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The molecular mechanisms of general anesthetic action are poorly understood, 
especially in regard to widely used inhaled anesthetic agents. Optimization of 
anesthetic drug design and clinical use requires detailed understanding of the roles of 
specific targets involved in the therapeutic actions (unconsciousness, amnesia, 
immobility) and undesirable effects (cardiovascular and respiratory depression, 
neurotoxicity) of various anesthetics. Voltage-gated sodium channels (Nav) have been 
implicated as targets for anesthetic inhibition of neurotransmitter release, but block of 
Nav by general anesthetics was previously considered too modest at clinical 
concentrations to be pharmacologically relevant. However, studies in whole animals 
show that block of Nav by the prototypical inhaled anesthetic agent isoflurane is 
necessary for producing immobility and determining anesthetic potency.  
This dissertation addresses the electrophysiological effects of isoflurane on Nav 
and the presynaptic action potential in primary cultures of rat hippocampal neurons. At 
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concentrations equivalent to those used in the clinic, isoflurane, and not the 
nonanesthetic molecule F6, significantly decreased spontaneous activity of 
hippocampal neurons and also reduced peak amplitude and upstroke velocity of the 
action potential. Peak current of endogenous Nav was inhibited ~10% by clinical 
concentrations of isoflurane, similar to previous reports. However, we found that the 
magnitude of Nav block depended on the state of the channel and increased at higher 
stimulation frequencies. Using heterologously expressed rat Nav1.2, a widely 
expressed neuronal isoform, we show that isoflurane stabilizes the fast-inactivated 
state of the channel. We propose that by stabilizing Nav in the inactivated state, 
isoflurane leads to accumulation of inactivated channels and inhibition of INa during 
trains of high frequency stimuli as would be experienced by a burst-firing neuron. This 
work shows that activity-dependent block contributes significantly to overall block of 
Nav, and supports a role for Nav inhibition in the presynaptic action of general 
anesthetic ethers such as isoflurane.  
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CHAPTER ONE 
INTRODUCTION 
 
General anesthesia is the reversible, pharmacological state of amnesia, 
unconsciousness, and immobility that can be induced by a remarkable variety of 
inhaled and intravenous agents (Franks, 2006; Rudolph and Antkowiak, 2004; Urban, 
2008). Despite widespread use and the invaluable role anesthetics play in modern 
medicine, the exact mechanism of action remains incompletely understood especially 
for the volatile anesthetics (VAs) (Campagna et al., 2003; Franks and Lieb, 1994; 
Hemmings, 2009; Solt and Forman, 2007). The first successful public demonstration 
of anesthesia during surgery was performed in 1846 at Massachusetts General 
Hospital by William T. G. Morton. Using a colorless gas, Morton sedated a patient 
while a surgeon removed a tumor from his neck. With some persuading, Morton later 
revealed the gas was ether, the medicinal properties of which had been known for 
centuries, and that had already been used during surgery by Dr. Crawford W. Long 
and colleagues in Georgia (Chivukula et al., 2014; Hudson et al., 2013). However, 
Morton’s public demonstration is largely credited with bringing general anesthesia 
into widespread clinical practice and marking the dawn of modern surgery.  
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In the mid-20th century fluorine chemistry led to the discovery of modern day 
VAs - fluorinated methyl ethyl ethers: enflurane, isoflurane, sevoflurane and 
desflurane that are less flammable than ether and have a better therapeutic index 
(Hudson et al., 2013; Terrell, 2008). Since the 1980’s, major advancements have been 
made towards the discovery of how these drugs work as the field has moved away 
from nonspecific lipid-based mechanisms of action to protein-target based 
mechanisms (Franks and Lieb, 1984).  
 The molecular pharmacology of the anesthetic state involves multiple target 
proteins, prominently including ligand-gated and voltage-gated ion channels (Eger et 
al., 2008; Franks and Lieb, 1994; Hemmings et al., 2005c; Krasowski and Harrison, 
1999). Research into understanding the mechanism of action of general anesthetics 
can lead to advances in both clinical practice and the field of neuroscience, since 
understanding how anesthetics work will tell us a good deal about consciousness itself 
(Arhem et al., 2003; Perouansky and Pearce, 2011). Elucidation of the mechanisms 
that produce the desired behavioral state (amnesia, unconsciousness and immobility) 
as well as those that cause undesirable side effects (cardiovascular and respiratory 
depression, neurotoxicity) will guide the development of safer drugs and lead to 
improved clinical outcomes (Grasshoff et al., 2006; Hemmings et al., 2005c; Solt and 
Forman, 2007). Furthermore, research into understanding the neuroprotective effects 
of general anesthetics can also indentify protein targets to protect against damage 
induced by ischemia, stroke, and neurodegenerative disease (Li and Zuo, 2009; Sun et 
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al., 2015; Yin et al., 2012; Zhao and Zuo, 2004) and could guide the selection of 
anesthetics to optimize neurologic outcomes (Schifilliti et al., 2010).  
 
Bioelectricity and neuronal communication in the central nervous system 
 Drugs that produce anesthesia interfere with the electrical and chemical 
signalling between neurons, which are the principal cells of the central nervous system 
(CNS) (Figure 1). Neurons have a cell body, called the soma, out from which extends 
large filipodial-like protrusions called dendrites that receive incoming chemical 
stimuli and convert it into electrical signals. The space between two communicating 
neurons is called the synapse, and information is sent primarily from the ‘presynaptic 
neuron’ to the ‘postsynaptic neuron’.  
The cell membrane is composed of a lipid bilayer that, due to its 
hydrophobicity, is impermeable to charged molecules and separates the ionic milieu of 
the cytosol from the extracellular space. The Na+/K+ pump exchanges Na+ and K+ 
against their concentration gradients and maintains a relatively high [K+] inside the 
cell and relatively high [Na+] outside.  When the neuron is at rest, the inside of the 
membrane is negative with respect to the outside, producing a voltage of ~−60 mV. 
The action potential (AP) is an electrical signal that transmits information in the 
neuron and is produced through the coordinated opening and closing of voltage-gated 
proteins that span the cell membrane and form hydrophilic channels that selectively 
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pass Na+ or K+ current (Armstrong and Bezanilla, 1973; Hille, 1967; Hodgkin and 
Huxley, 1952; Nakamura et al., 1965) (Figure 1). When the channel for a particular 
FIGURE 1. Electrical and chemical signalling in the neuron. Cartoon of a 
presynaptic neuron synapsing onto the dendrites of a postsynaptic neuron. Expanded 
view of the AIS shows a neuronal action potential (AP) with contributions from 
voltage-gated Na+ and K+ channels indicated in green and blue, respectively. Arrows 
indicate direction of current flow through the channels. Expanded view of the 
synapse shows the incoming AP and Ca2+ entry causing synaptic vesicles to fuse to 
the presynaptic membrane.  Excitatory neurotransmitters (red) open cation channels 
(red, +) and inhibitory neurotransmitters (blue) open anion channels (turquoise, −) 
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ion is open, the current (Iion) is driven by an electrochemical gradient due to the ion 
concentration inside and outside of the cell, and the membrane voltage (Vm). The 
equilibrium potential (Eion) is the Vm where the concentration gradient and the 
electrical driving force balance each other and there is no net current flow. 
Alternatively, the further Vm is from Eion, the greater the electrical driving force for 
that ion.  
Voltage-gated Na+ channels (Nav) are closed at hyperpolarized potentials and 
the equilibrium potential for Na+, ENa=+60 mV. Therefore, when Nav open at ~−30 
mV, Na+ current (INa) flows into the cell and rapidly depolarizes the membrane, 
creating the upstroke of the AP. Nav inactivate within milliseconds after opening, 
halting the upstroke of the AP (Aldrich et al., 1983; Armstrong and Bezanilla, 1977; 
Cota and Armstrong, 1989) and the now depolarized Vm creates the driving force for 
K+ (EK=~−90 mV), to move out of the cell and repolarize the membrane. Upon 
membrane repolarization, Nav recover from inactivation and return to the resting state.  
The AP propagates down the axon, which is a long thin process that extends 
from the soma (Boiko et al., 2003; Carras et al., 1992; Stuart et al., 1997) to 
varicosities that emerge en passant or at the axon terminals called boutons. Boutons 
contain lipid-bound vesicles packed with neurotransmitter molecules that are released 
into the synapse during exocytosis. The depolarization of the membrane during the AP 
opens voltage-gated Ca2+ channels (Cav), which pass Ca
2+ into the cell where it binds 
machinery that facilitates fusion of synaptic vesicles with the plasma membrane, 
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which results in release of neurotransmitters into the synapse. The boutons of the 
presynaptic neuron are apposed to neurotransmitter receptors on dendrites or the soma 
of the postsynaptic neuron across the synapse. These receptors are ‘ligand-gated’ ion 
channels (LGICs) and can be excitatory, such as AMPA and NMDA receptors that 
open cation channels and cause membrane depolarization, or inhibitory, such as 
GABAA and glycine receptors that open Cl
- channels and cause the membrane to 
hyperpolarize (Figure 1). Glutamate is the major excitatory neurotransmitter in the 
CNS and GABA is the major inhibitory neurotransmitter. Neurons are often referred 
to by the neurotransmitters they release or by the actions of those neurotransmitters 
(e.g. GABAergic/inhibitory neurons or glutamatergic/excitatory neurons).  
 
Pharmacology of general anesthetics  
 General anesthetics induce a reversible, drug-induced loss of consciousness 
with a unique pharmacology. The use of general anesthesia requires immediate onset 
and reversibility of the drug effect as opposed to more conventional therapeutics that 
can take days or weeks to reach full effect. General anesthetics also have a very 
narrow therapeutic index; concentrations that cause toxic or lethal side effects are only 
2 – 4 times that used for anesthesia. However, dose-response curves for anesthetics are 
very steep, meaning only slight changes in drug concentration exert large effects on 
physiological response (Hemmings et al., 2005b). This is important because it allows 
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the anesthesiologist to keep the administered dose close to the EC50, which avoids 
toxic side effects and allows for quick reversibility of the anesthetic state.   
Some of the most widely used general anesthetics are inhaled or gaseous 
agents. This class of drugs include halogenated ethers that are referred to as ‘volatile’ 
anesthetics (VAs), which reflects their tendency to vaporize at room temperature and 
standard pressure. VAs are small lipophilic molecules that can easily pass through cell 
membranes and into the blood stream from the lung where they quickly reach the 
well-perfused CNS. Potency of inhaled anesthetics is measured as the exhaled 
concentration at steady-state, and is referred to as minimum alveolar concentration 
(MAC),  which is the concentration at which 50% of patients do not respond to a 
surgical incision (Eger et al., 1965). MAC, determined using immobility as the 
endpoint, translates to aqueous concentrations in the hundreds of micromolar to 
millimolar range for commonly used volatile anesthetics (Franks and Lieb, 1994). 
However, the concentrations of drug needed for half maximal effect of amnesia and 
unconsciousness are a fraction of MAC, which indicates that these behavioral 
endpoints are mediated by distinct neural circuits and/or target proteins.  
VAs are minimally metabolized by cytochrome P450 enzymes in the liver 
(Kharasch and Thummel, 1993; Spracklin et al., 1996); the extent to which these 
anesthetics are metabolized determines their level of hepatic  and renal toxicity 
(Hudson et al., 2013).  VAs with high rates of metabolism, such as halothane that is 
40-60% metabolized, have a high risk of ‘halothane hepatitis’, which has subsequently 
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reduced its use in the clinic  (Cohen, 1978; Safari et al., 2014). Isoflurane is used 
widely in part because of its very low (<0.1%) rate of metabolism and sevoflurane is 
also considered relatively non-toxic because it is poorly metabolized (Pihlainen and 
Ojanperä, 1998; Safari et al., 2014). 
 
Mechanisms of general anesthetic action 
Until the late 20th century, the structural diversity of general anesthetics 
cultivated the idea of a common, nonspecific mechanism of action (Franks, 2006; 
Hemmings et al., 2005c; Kopp Lugli et al., 2009).  The Meyer-Overton correlation 
describes a direct correlation between anesthetic potency and lipid solubility (Meyer, 
1899; Overton, 1901; Perouansky, 2012). This led to lipid-based theories of anesthetic 
action that implied that anesthetics act by dissolving into the lipid bilayer and 
disrupting the cell membrane. Lipid-based theories dominated the field for the 
majority of the 20th century but, following the introduction of the fluorinated methyl 
ethyl ethers in the 1960s, failed to explain the differences in potency in vivo between 
enantiomers of inhaled anesthetics such as isoflurane that have a chiral carbon 
(Dickinson et al., 1994; Koblin et al., 1981; Lysko et al., 1994). Also, the discovery of 
lipophilic halogenated hydrocarbons that lack anesthetic potency and therefore 
disobey the Meyer-Overton correlation proved incongruous to lipid-based theories of 
anesthetic action (Koblin et al., 1994; Perouansky, 2008).   
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In the 1980’s Franks and Lieb redirected the focus from nonspecific lipid-
based theories to identifying specific protein targets of general anesthetics (Franks and 
Lieb, 1978; Franks and Lieb, 1982). Using purified firefly luciferase, they 
demonstrated that anesthetics bind the protein in the absence of lipid and displace 
luciferin, the endogenous ligand (Franks and Lieb, 1984). Today many targets have 
been identified, mostly voltage- and ligand-gated ion channels. Targets for general 
anesthetics have to show a reversible response to clinical concentrations of drug, 
stereoselectivity in vitro matching that in vivo, and a lack of response to nonanesthetic 
agents (Franks and Lieb, 1994; Hemmings et al., 2005c).  
It is now widely accepted that the behavioral endpoints of general anesthesia 
arise from different areas and circuits within the CNS. For a protein to be considered a 
plausible target, it must be expressed in the area of the CNS that gives rise to the 
relevant behavioral endpoint (Hemmings et al., 2005c). Immobility arises from 
anesthetic effects in the spinal cord (Sonner et al., 2003). This was discovered through 
experiments in rats that showed isoflurane retains the ability to depress motor reflexes 
in response to noxious stimuli even when the brain is disconnected from the spine 
(Rampil, 1994; Rampil et al., 1993). Amnesia arises from the regions in the forebrain 
important for learning and memory such as the hippocampus and cerebral cortex 
(Caraiscos et al., 2004; Rau et al., 2011; Wang and Orser, 2011). The neuronal 
correlates of unconsciousness are less clear and are generally thought to include areas 
of the cortex, thalamus and brainstem (Alkire et al., 2000; Rudolph and Antkowiak, 
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2004) and may involve hypothalamic sleep-promoting pathways as well (Han et al., 
2014; Zecharia et al., 2009).  
General anesthetics enhance inhibitory postsynaptic currents, depress 
excitatory postsynaptic currents and depress exocytosis of excitatory neurotransmitters 
(Hemmings, 2009). A number of ion channels, mostly postsynaptic LGICs, have been 
identified as targets for general anesthetics, but no one target is sufficient to explain 
the behavioural state induced by any given anesthetic. GABAA receptors (GABAAR) 
are LGICs found mainly in the brain that pass inhibitory Cl- current. These channels 
have emerged as important anesthetic targets since they are potentiated by a wide 
variety of general anesthetics and account for a majority of the effects of the widely 
used intravenous anesthetic propofol (Krasowski and Harrison, 1999). While 
GABAAR plays more of a role in the mechanism of action of propofol than VAs 
(Kungys et al., 2009; Sonner et al., 2007; Wakasugi et al., 1999), the amnestic effects 
of isoflurane are attributed to enhancement of GABAAR since forebrain-specific 
knock-down of essential GABAAR subunits prevent the amnestic effects of isoflurane 
in mice (Rau et al., 2009; Rau et al., 2011). Extrasynaptic GABAARs in the thalamus 
and hippocampus, which produce tonic inhibitory postsynaptic currents, are especially 
sensitive to VAs (Caraiscos et al., 2004; Jia et al., 2008) and play a role in isoflurane-
induced amnesia and sedation (Orser, 2006; Wang and Orser, 2011; Zurek et al., 
2012). Effects on GABAARs cannot however, explain immobility produced by VAs 
(Kim et al., 2007; Werner et al., 2011). 
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VAs have a number of other targets that they modulate at clinically relevant 
concentrations (Figure 2). Glycine receptors (GlyR) are inhibitory postsynaptic LGICs 
found mainly in the spinal cord that are potentiated by VAs and contribute to their 
immobilizing effects (Zhang et al., 2003). VAs also inhibit excitatory postsynaptic 
currents by blocking NMDA (Nishikawa and MacIver, 2000; Wakasugi et al., 1999), 
AMPA (de Sousa et al., 2000) and nicotinic acetylcholine receptors (nAChRs) 
(Hudson et al., 2013). Postsynaptic effects of VAs also include potentiation of outward 
K+ current through 2-pore K+ leak channels (K2P) which hyperpolarizes the 
membrane (Sirois et al., 2000; Westphalen et al., 2007; Winegar et al., 1996) and 
desensitizes the neuron to excitatory input (Berg-Johnsen and Langmoen, 1990).  
VAs also have presynaptic effects, which cause a reduction in excitatory 
neurotransmitter release (Maclver et al., 1996; Perouansky et al., 1995; Schlame and 
Hemmings, 1995). Direct evidence shows that isoflurane inhibits exocytosis 
(Hemmings et al., 2005a; Winegar and MacIver, 2006) and this inhibition is selective 
for glutamatergic over GABAergic terminals (Westphalen and Hemmings, 2006). 
Presynaptic effects indicate actions on the voltage-gated Na+, K+, and Ca2+ channels 
that underly the AP and exocytosis. However, experiments on myelinated mammalian 
nerve fibers previously showed that AP propogation is not affected by clinical 
concentrations of VAs (Larrabee and Posternak, 1952). This led to the idea that VAs 
have no effect on voltage-gated ion channels. However, more recent studies show 
conduction along unmyelinated nerve fibers are sensitive to clinical concentrations of 
VAs (Berg-Johnsen and Langmoen, 1986; Mikulec et al., 1998). Moreover, isoflurane 
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inhibits the presynaptic AP in glutamatergic nerve terminals (Ouyang and Hemmings, 
2005; Wu et al., 2004). Isoflurane inhibits low-voltage activated T-type Ca2+ channels 
that underlie burst firing in thalamocortical neurons (Orestes et al., 2009) as well as 
presynaptic high-voltage activated L- and R-type channels in the hippocampus and 
thalamus (El Beheiry et al., 2007; Joksovic et al., 2009). There is also some, albeit 
conflicting evidence that VAs inhibit N- and P/Q type channels in heterologous 
expression systems (Orestes and Todorovic, 2010).   
 
 
Voltage-gated sodium channels as targets for general inhaled anesthetics 
 Voltage-gated sodium channels (Nav) are essential components of all excitable 
cells in that they underlie the depolarization of the membrane during the AP. Nav are 
FIGURE 2. Putative 
targets of volatile 
anesthetics. Diagram 
of protein targets at the 
synapse. VAs inhibit 
presynaptic Nav, Kv 
and Cav  subtypes 
(indicated in gray). 
VAs inhibit excitatory 
postsynaptic receptors 
(shown in red) and 
enhance inhibitory 
postsynaptic and 
extrasynaptic 
receptors (turquoise) 
and postsynaptic 2-
pore K+ leak channels 
(blue).    
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large macromolecular complexes embedded in the cell membrane that selectively 
allow Na+ to pass through. The pore forming α-subunit of Nav contains 4 domains 
with 6 transmembrane domains each (S1-S6). Nav are closed at hyperpolarized 
membrane potentials and open when positively charged residues in the S4 
transmembrane segment move outward in response to membrane depolarization and 
open the channel (Catterall, 2002; Cestèle et al., 2006) (Figure 3). Channels rapidly 
enter an inactivated state after opening and are unavailable for opening upon 
membrane depolarization. Nav have rapid gating kinetics and cycle through these 
states within a matter of milliseconds.  
There are nine mammalian isoforms of Nav that share significant sequence 
homology and have similar gating kinetics (Goldin et al., 2000; Mechaly et al., 2005). 
However, distinct expression patterns of the different subtypes points to a 
specialization of subtype function (Goldin, 2001; Gordon et al., 1987). Nav1.1, Nav1.2 
and Nav1.6 are found in the adult mammalian brain (Beckh et al., 1989) with Nav1.7 
Nav1.8 and Nav1.9 mainly found in the periphery (Goldin, 2001). Nav1.4 and Nav1.5 
are found in skeletal and heart muscle, respectively, with Nav1.5 also expressed in the 
entorihnal cortex where it maintains distinctive ‘cardiac Nav-like’ properties (White et 
al., 1993). Nav1.5, along with Nav1.8 and Nav1.9, are relatively resistant to the puffer 
fish toxin tetrodotoxin (TTX) which blocks all major CNS isoforms in the nanomolar 
range (Goldin, 2001). The pore-forming ‘α-subunit’ of Nav is transcribed from a single 
gene that undergoes alternative splicing and also assembles with auxillary β-subunits 
and scaffolding proteins that modulate channel activity and surface expression to add 
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to the diversity of possible Nav complexes (Goldin, 2001; Isom, 2001). Nav  are also 
highly regulated by phosphorylation in vivo which mediates expression, localization 
and channel activity (Baek et al., 2011; Berendt et al., 2010). 
 
 
The subcellular distribution and cell-type specific expression profiles highlight 
the various cellular functions of Nav. A high concentration of Nav in the AIS is 
FIGURE 3. Voltage-gated sodium channel topology and conformational states. 
Top, Topology of the Nav α-subunit containing 4 domains each with 6 transmembrane 
segments (S1-S6). Positively charged residues in S4 are indicated with ‘+’. The loop 
between S5-S6 of domain I contains the TTX binding site and the loop between 
domains III and IV is the inactivation gate. The single-transmembrane spanning β 
subunit is shown in blue. Bottom, Conformation states of Nav: ‘Resting’, ‘Open’, and 
‘Inactivated’. Membrane voltage indicated by +/−. 
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necessary for AP generation (Colbert and Johnston, 1996). In the AIS of excitatory 
neurons that mainly express Nav1.2 and Nav1.6, Nav1.2 is concentrated proximal to the 
cell body and Nav1.6 is more concentrated distally (Boiko et al., 2003). Due to the 
more hyperpolarized activation voltage of Nav1.6 (Rush et al., 2005) and its distance 
from the soma (Kress et al., 2010), the AP is generated in the distal region of the AIS 
and propagates down the length of the axon. APs also backpropogate into the soma 
and the dendrites since  Nav1.2 is activated only after the AP is generated (Hu et al., 
2009).  The backpropogation of APs into dendrites regulates incoming stimuli (Jung et 
al., 1997; Kole and Stuart, 2012). Nav1.1 makes up only 10% of brain Nav (Gordon et 
al. 1987). There is evidence that Nav1.1 is specifically expressed in GABAergic 
neurons where it is found in the AIS and nodes of Ranvier (Lorincz and Nusser, 2008). 
This poses an interesting question of whether the greater anesthetic sensitivity of 
glutamate release compared to GABA could be due to differences in Nav subtype 
expression.  
In unmyelinated central axons there is a high density of Nav in presynaptic 
terminals suggesting that the AP is actively regenerated in boutons rather than 
passively transmitted (Engel and Jonas, 2005). Nav1.2 is the predominant isoform in 
unmyelinated axons in the CNS (Boiko et al., 2001) and has been detected on the 
presynaptic membrane of hippocampal neurons using immunoelectron microscopy 
(Lorincz and Nusser, 2010). Nav1.6 is the predominant isoform in myelinated axons 
and has been shown to be both pre- and postsynaptic in cortical neurons (Boiko et al., 
2001; Caldwell et al., 2000). The subcellular distribution of Nav may play a key role in 
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understanding anesthetic sensitivity and cell-type specific effects of anesthetics. 
Different Nav subtypes may be expressed in the axon as opposed to the bouton for 
example, and the relative sensitivity of Nav subtypes to general anesthetics may 
determine effects on neurotransmitter release.  
A role for Nav in the modulation of neurotransmission by general anesthetics is 
supported by evidence that presynaptic blockade of Na+ current (INa) contributes to 
suppression of the release of multiple neurotransmitters by VAs (Hemmings et al., 
2005a; Westphalen and Hemmings, 2003; Wu et al., 2004). Isoflurane blocks multiple 
subtypes of Nav (Herold et al., 2009; Ouyang and Hemmings, 2007; Rehberg et al., 
1996; Shiraishi and Harris, 2004), and reduces AP amplitude in rat hippocampal 
neurons (Berg-Johnsen and Langmoen, 1990), isolated rat neurohypophysial terminals 
(Ouyang and Hemmings, 2005) and rat Calyx of Held (Wu et al., 2004).  
Intrathecal delivery of the highly specific Nav inhibitor tetrodotoxin (TTX) in 
adult rats enhances isoflurane potency in producing immobilization, a primarily spinal 
cord-mediated effect, whereas the Nav activator veratridine reduces isoflurane potency 
and antagonizes the effect of TTX (Zhang et al., 2010). Futhermore, altered 
concentrations of Na+ in the spinal cord, but not in the brain, have been shown to 
affect MAC, arguing that a protein regulated by the Na+ gradient is a target for 
isoflurane in the spinal cord (Laster et al., 2007). 
Drugs that block Nav are often state-dependent, that is they have a greater 
affinity for one state of the channel, be it open, closed, inactivated (Figure 3), or some 
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other intermediate state (Fozzard et al., 2005; Ragsdale et al., 1994). This is the case 
for local anesthetics that preferentially bind open or inactivated Nav with greater 
potency (~30 µM) than Nav in the resting state (~300 µM) (Nau and Wang, 2004; 
Wang et al., 2004). This phenomenon makes the potency of the drug dependent on the 
activity of the channel and the voltage of the membrane. Isoflurane alters the voltage-
dependence of Nav1.2 gating in vitro (Ouyang et al., 2003; Rehberg et al., 1996; 
Shiraishi and Harris, 2004), which indicates block of Nav by isoflurane is state-
dependent.  
This dissertation focuses on the mechanism of action of the widely used 
inhaled anesthetic isoflurane as it pertains to Nav. We measure the effects of clinical 
concentrations of isoflurane on neuronal excitability in cultures of neonatal rat 
hippocampal neurons. Hippocampal neurons form extensive synaptic connections after 
7 DIV and allow us to study the effects of isoflurane on spontaneous AP firing as well 
as intrinsic membrane excitability. Dissociated hippocampal neurons also retain 
electrophysiological properties in vitro similar to those seen in slice recordings (Kay 
and Wong, 1986). We further investigate the effects of isoflurane on Nav in a 
heterologous system expressing recombinant rNav1.2, the most abundant Nav isoform 
in unmyelinated axons of central neurons (Boiko et al., 2001). We use this system to 
measure changes in Nav voltage-dependance and gating kinetics in the presence of 
isoflurane. We find that isoflurane at clinical concentrations has significant effects on 
Nav and neuronal excitability and we discuss these findings in the context of modern 
theories of anesthetic action.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Materials 
Isoflurane was obtained from Abbott Laboratories (North Chicago, IL). TTX 
was purchased from Sankyo Kasei (Tokyo, Japan). Amphotericin B, 
tetraethylammonium chloride (TEACl), and other chemical reagents were purchased 
from Sigma-Aldrich (St. Louis, MO). E16 – E18 pregnant Sprague-Dawley rats were 
purchased from Charles River Laboratories (Wilmington, MA). 
 
Anesthetic solutions 
External bath solutions were saturated with isoflurane (12-12.5 mM; Abbott 
Laboratories, North Chicago, IL) and diluted to final concentrations of 0.45-0.5 mM in 
gas-tight glass syringes. Isoflurane solutions were perfused using a pressure driven 
microperfusion system (ALA BPS-8; ALA Scientific, Westbury, NY) positioned 100-
150 µm away from the cell. Concentrations of isoflurane sampled at the perfusion 
pipette tip were measured using a Shimadzu GC-2010 Plus gas chromatograph 
(Shimadzu, Tokyo, Japan) following extraction into octane (1:1 v/v), and reflected 
~10% loss from the syringe to the bath (Herold et al., 2009). 
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Solutions of 1,2-dichlorohexafluorocyclobutane (F6) were prepared in the 
same manner with the saturated solution (0.25 mM) diluted to final concentrations of 
0.025mM (2 MAC). 
  
Primary rat hippocampal neuron cultures 
Animal protocols were approved by the Institutional Animal Care and Use 
Committee of Weill Cornell Medical College. Postnatal Day 1 Sprague-Dawley rats 
(Charles River Laboratories) were decapitated and the hippocampus dissected out and 
chopped into pieces in ice cold HBSS + 20% FBS (GIBCO). Tissue was washed in 
HBSS and digested in 10mg/mL trypsin (Sigma-Aldrich) for 5 minutes at RT. Cells 
were dissociated by pipetting up and down in HBSS with 1mg ml-1 DNAse (Sigma-
Aldrich). Cells were spun down in HBSS + 20% FBS, 1300 rpm for 10 min and plated 
cells 250,000 cells mL-1 on glass coverslips coated with poly-D-lysine and laminin 
(BD Biosciences, East Rutherford, NJ). The anti-mitotic cytosine arabinoside (Ara-C) 
was added to the media after 36 hours and cells were patched after 7-14 DIV. 
 
Cell culture and Nav transfection of ND7/23 cells 
Neuroblastoma ND7/23 cells  were plated on 12-mm glass coverslips and 
incubated in a humidified atmosphere at 37°C in 5% CO2 in Dulbecco’s modified 
Eagle’s medium supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 
100 U ml-1 penicillin and 100 μg ml-1 streptomycin (all reagents from Sigma-Aldrich 
unless specified).  
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Wild-type rat Nav1.2a (accession number NM_012647) was kindly provided 
by Prof. William Catterall (University of Washington, Seattle). TTX-resistance was 
engineered into Nav1.2a by site-directed mutagenesis (F385S) (Leffler et al., 2005) 
(referred to as Nav1.2R) to allow isolation from endogenous channels and expression in 
a neuronal background, which is crucial to measuring the effect of isoflurane on Nav in 
heterologous expression systems (Herold et al., 2009). Cells were transiently 
transfected with Nav1.2R and pEGFP-N1 (Clontech, Mountain View, CA) cDNA using 
Lipofectamine LTX (Invitrogen, Carlsbad, CA) to allow identification of transfected 
cells by eGFP fluoresence imaging. Experiments were performed in the presence of 
250 nM tetrodotoxin (TTX; Sankyo Kasei, Tokyo, Japan) to block endogenous INa.  
 
Electrophysiological recording of ND7/23 cells 
Whole-cell patch-clamp experiments were performed at room temperature (23-
24°C) using an Axopatch 200B amplifier (Axon Instruments, Burlingame, CA), 
digitized via a Digidata 1321A interface, and analysed using pClamp 10.2 software 
(Axon Instruments). Whole-cell currents were sampled at 50 kHz and low-pass 
filtered at 5 kHz. Whole-cell seal resistance was 2–8 GΩ prior to patch rupture. Pipette 
resistance was 1.5-2.5 MΩ when filled with internal solution containing (in mM): 120 
CsF, 10 NaCl, 10 HEPES, 10 EGTA, 10 TEA-Cl, 1 CaCl2, and 1 MgCl2 and adjusted 
to pH 7.3 (with CsOH) and 310 mOsm kg-1 H2O. External solution contained (in mM): 
130 NaCl, 10 HEPES, 3.25 KCl, 2 MgCl2, 2 CaCl2, 20 TEA-Cl, 5 D-glucose, 0.00025 
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TTX and was adjusted to pH 7.4 with NaOH and 310 mOsm kg-1 H2O with sucrose. 
The liquid–junction potential (~7.8 mV) was not corrected.  
Only cells expressing 2-8 nA of peak current were analysed in order to 
minimise space clamp and series resistance errors. Capacitive transients were 
electronically cancelled and voltage error was minimised using 70-80% series 
resistance compensation. Series resistance was typically 2–4 MΩ and data were 
discarded if >10 MΩ. Experiments began 5 min after attaining whole-cell patch to 
allow equilibration of the pipette solution with the cytosol. Voltage protocols were 
applied from a holding potential (Vh) of −70 mV or −90 mV with 5 s intervals 
between sweeps. Protocols were applied in control solution and again after 5 min 
perfusion with isoflurane. Perfused cells showed stable responses (rundown <10%) for 
up to 5 min in control experiments (data not shown). Linear leak currents were 
subtracted using the P/4 method (Bezanilla and Armstrong, 1977). 
 
Stimulation protocols  
Current-voltage (I-V) relationships were determined by measuring the peak 
current at a series of 10-ms voltage commands ranging from -50 mV to +30 mV in 10-
mV steps applied at 5-s intervals using a holding potential (Vh) of either -70 mV or -
90 mV. Voltage steps were preceded by a 50-ms prepulse to -100 mV to relieve Nav 
from inactivation. The relationship between conductance (G) and voltage was derived 
from the I-V relationship using the equation G = I/(V-Vrev), where I is the peak INa at a 
given voltage (V) and Vrev is the measured Na
+ reversal potential. Normalized 
conductance values (G/Gmax) were fit to the Boltzmann equation G/Gmax = 1/[1 + 
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exp(V1/2 - V/k)], where V1/2 is the voltage at half-maximal activation and k is the slope 
factor. Steady-state inactivation was measured using a two-pulse protocol consisting 
of a 50-ms prepulse to voltages ranging from −100 mV to −20 mV in 10-mV 
increments followed by a 10-ms pulse to 0 mV. Normalized peak current (INa/INamax) 
was plotted against prepulse voltage and fitted with a Boltzmann function.  Recovery 
from inactivation was measured at Vh of −70 or −90 mV by administering two 5-ms 
pulses to 0 mV separated by a recovery period of increasing durations from 1 – 100 
ms. INa of the second pulse was divided by INa of the first pulse (Pulse2/Pulse1) and 
plotted against the time of the interpulse interval and fitted with a single exponential 
equation. The onset of inactivation was measured using a pulse to 0 mV for increasing 
durations of 0.7 to 50 ms, followed by a brief 2-ms return to Vh (−90 mV) before a test 
pulse to 0 mV for 5 ms.  The ratio of INa for Pulse2/Pulse1 was plotted against the 
duration of the first pulse and fit with a mono-exponential function.   
 
Activity-dependent block was quantified by administering 50-Hz trains of 
either 5- or 15-ms pulses to 0 mV for 200 ms from Vh of −70 or −90 mV. INa for each 
pulse was normalized to INa of Pulse 1 (Pulsen/Pulse1) and plotted against pulse 
number. Data were fitted to the mono-exponential function Pulsen/Pulse1 = exp(-
*n)+AP, where  is the time constant, AP is the plateau and n is stimulus number. To 
determine the kinetics of macroscopic inactivation, INa was elicited by a 5-ms pulse to 
0 mV from a Vh of −70 mV. Current traces from paired control and isoflurane 
experiments were normalized to peak INa and the decay phases were fit with a bi-
exponential equation. 
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Statistical analysis 
Data were analysed using Prism v6.05 (Graph-Pad Software Inc., San Diego, 
CA) and SigmaPlot 6.0 (SPSS Science Software Inc., Chicago, IL). Conductance (G) 
values were derived from the I-V relationship using the equation G = I/(V-Vrev), where 
I is the peak INa at a given voltage (V) and Vrev is the measured Na
+ reversal potential. 
Voltages at half-maximal activation (V½act) were obtained from fitting the data for 
each cell to a Boltzmann equation of the form G/Gmax = 1/[1 + exp(V½act - V/k)], 
where G/Gmax is the normalized fractional conductance and k is the slope factor. The 
voltage at which fast inactivation is half-maximal (V½) was measured by fitting 
normalized steady-state INa values to a Boltzmann function of the form INa/INamax = 
1/[1 + exp(V½ - V/k)]. Time course data were fitted to the mono-exponential function 
Y = exp(-*n)+AP, where  is the time constant, AP is the plateau and n is stimulus 
number. To determine the kinetics of macroscopic inactivation, the decay phase of the 
current trace was fit with a bi-exponential equation of the form A1• exp(–t/1) +A2• 
exp(–t/2) + B, where An is the nth component amplitude, B is the plateau, t is time and 
n are time constants.  
Data are expressed as mean [standard deviation, SD], and were analyzed using 
two-tailed paired Student’s t-test or ANOVA with post hoc testing as indicated, with 
statistical significance set as p=0.05. 
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CHAPTER THREE 
RESULTS 
 
Isoflurane reduces spontaneous activity of isolated hippocampal neurons 
First we determined the effects of isoflurane on the spontaneous activity of 
hippocampal CA2/3 pyramidal neurons cultured for 10-14 DIV. We recorded from 
actively firing neurons with a ‘pyramidal-like’ morphology and RMP  between −55 
and −65 mV and measured responses to concentrations of isoflurane that produce 
anesthesia in rats [0.42 mM; equivalent to ~1.5 times MAC (minimum alveolar 
concentration)] (Taheri et al., 1991).  We also applied the nonimmobilizer 1,2-
dichlorohexafluorocyclobutane (F6), which is a small halogenated hydrocarbon that 
disobeys the Meyer-Overton correlation in that it lacks anesthetic potency at 
concentrations predicted by its lipophilicity (Perouansky, 2008).  
Neurons fired spontaneously in culture for up to 15 min as APs were recorded 
passively using the whole-cell configuration in current-clamp mode. We recorded 
spontaneous activity in the absence or presence of F6 and isoflurane and measured the 
frequency of AP firing in the final minute of each 3 min perfusion. Isoflurane 
significantly reduced firing frequency by 87% compared to control (CTL=6.1±1.1 Hz, 
vs. ISO=0.8±0.4 Hz, n=4, **p=0.003, one-way ANOVA and Tukey’s post-hoc test)  
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whereas F6 had no effect (CTL=6.1±1.1 Hz, vs. F6=6.0±0.9 Hz, n=4, n.s.) (Figure 4). 
To test whether this effect of isoflurane was reversible, we washed with control buffer 
for 5 min following perfusion with isoflurane. Firing frequency was determined by 
counting the number of APs in the last minute of perfusion. Isoflurane significantly 
lowered firing frequency compared to control (CTL= 4.5±1.2 Hz vs. ISO= 0.8±0.4 Hz 
, n=5, mean±SD, **p=0.009), and this effect was reversible upon washout (ISO= 
0.8±0.4 Hz, vs. WASH= 3.9±1.3 Hz, n=5, *p=0.01; CTL= 4.5±1.2 Hz vs. WASH= 
3.9±1.3 Hz , n=5, n.s., one-way ANOVA w/ Tukey’s post hoc test) (Figure 5).  
 
FIGURE 4. Isoflurane but not the nonimmobilizer F6 inhibits spontaneous 
activity of hippocampal neurons. Top, A spontaneously firing cultured rat 
hippocampal neuron superfused with 2 MAC 1,2-dichlorohexafluorocyclobutane 
(F6) for 3 min followed after 1 min by 1.5 MAC isoflurane for 3 min. Lower left, 
Structure of F6 and isoflurane. Lower Right, Average firing frequency (Hz) of 4 cells 
in control (6.1±1.1 Hz), during the last minute of F6 perfusion (6.0±0.9 Hz) and 
during the last minute of isoflurane perfusion (ISO, 0.8±0.4 Hz). Data are presented 
as mean±SD and tested with one-way repeated measures ANOVA and Tukey’s post-
hoc test.  
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In approximately 1 out of every 5 neurons, firing activity was characterized by 
prominent waves of membrane depolarization that lasted a few seconds and were 
Control 
n= 5   
mean±SD 
Isoflurane Washout 
FIGURE 5. Isoflurane reversibly inhibits spontaneous firing activity in 
hippocampal neurons. Top panels from left, 10 s segment of action potential firing 
in control, in the presence of ~1.5 MAC isoflurane, and after 5 min washout of 
isoflurane. Dotted line denotes 0 mV, scale bar = 2 s. Average firing frequencies of 5 
cells in all three conditions (CTL= 4.5±1.2 Hz, ISO= 0.8±0.4 Hz, WASH= 3.9±1.3 
Hz). Data are presented as mean±SD and are compared using a one-way repeated 
measures ANOVA with Tukey’s post-hoc test *p<0.05, **p<0.01 
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crowned by bursts of APs (Figure 6). These cells were analyzed separately using the 
area under the raised membrane potential to estimate Ca2+ current and the crowning 
spikes as a measure of Na+ and K+ current (Huguenard, 1996).  In control and 
isoflurane conditions, the area under the raised membrane potential was similar (CTL= 
15±5 vs. ISO= 13±5 [AU], n=3, mean±SD, n.s. p=0.2, two-tailed, paired Student’s t-
test), but isoflurane significantly decreased the number of spikes per wave (CTL= 
8.4±2.7 vs. ISO= 3.8±2.0, n=3, mean±SD, *p=0.01, two-tailed, paired Student’s t-
test). Together these results indicate Nav or Kv are more sensitive to isoflurane than 
Cav in these neurons. 
 
 
FIGURE 6. Isoflurane significantly decreases the number of spikes but does not 
affect the size of Ca2+ waves in hippocampal neurons. Top, 30 s traces of spontaneous 
activity in control and in the presence of isoflurane. Right, cartoon of ionic currents 
underlying this type of spontaneous activity. Bottom left, Area under the curve in control 
(15.1±4.6) and in the presence of isoflurane (13.2±4.8, n=3, mean±SD, n.s.). Average 
number of spikes per wave in a 1 min period for 3 different neurons in control (8.4±2.7 
spikes wave-1) and isoflurane (3.8±2.0 spikes wave-1, mean±SD, *p=0.01, two-tailed, 
paired Student’s t-test).  
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We next looked more closely at the AP waveform since effects on Nav or Kv 
alter the shape of the AP, which could consequently lead to altered Ca2+ influx and 
neurotransmitter release (Borst and Sakmann, 1999; Boudkkazi et al., 2011; Kole et 
al., 2007). We overlaid APs that were passively recorded in control and in the 
presence of ~1.5 MAC isoflurane. Control and isoflurane APs recorded from the same 
neuron were compared based on the resting membrane potential immediately 
preceding the AP, since this could strongly affect the shape of the AP (Gong et al. 
2008). We compared APs initiated from the resting membrane potential (~−60 mV) as 
opposed to spikes elicited from on top of a depolarizing Ca2+ wave. Data collected 
from 5 neurons showed that ~1.5 MAC isoflurane significantly decreased AP 
amplitude (CTLAP amplitude=92±6 mV vs. ISOAP amplitude=67±13 mV, n=4, *p=0.03, two-
tailed paired Student’s t-test) (Figure 7). This effect could indicate a decrease in INa, 
accelerated Nav inactivation or accelerated activation of repolarizing Kv currents. We 
next measured the velocity of the upstroke of the AP and the threshold for AP firing, 
two parameters that are determined largely by Nav density and subtype expression 
(Bean, 2007; Hu et al., 2009). Isoflurane significantly decreased the velocity of the 
upstroke of the AP (CTLAP velocity= 120±14 dV/dt, vs. ISOAP velocity= 87±7 dV/dt, n=4, 
mean±SD, **p=0.009, two-tailed paired Student’s t-test) and also shifted the threshold 
for AP firing in a depolarizing direction (CTLAP threshold=−37±2 mV vs. ISOAP 
threshold=−32±2 mV, n=5, mean±SD, **p=0.007, two-tailed paired Student’s t-test) 
(Figure 7). 
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Isoflurane reduces intrinsic membrane excitability of hippocampal neurons.  
 When grown in culture, hippocampal neurons form extensive synaptic 
connections allowing for the generation of spontaneous activity. We determined 
whether the effects of isoflurane on Nav–dependent AP parameters stemmed from 
block of Nav or was a result of actions on postsynaptic LGICs that modulate incoming 
FIGURE 7. Effects of isoflurane on the presynaptic AP waveform in 
hippocampal neurons. Left, Representative APs recorded from the same cell in the 
absence (CTL) and presence of ~1.5 MAC isoflurane (ISO). Right, Parameters 
measured from paired APs in control or in the presence of isoflurane. Isoflurane 
reduced AP amplitude (CTL=92±6 mV vs. ISO=67±13 mV, *p=0.03), raised the 
threshold for AP firing (CTL=−37±2 mV vs. ISO=−34±2 mV, **p=0.007) and 
decreased the maximum rate of rise (CTL=120±14 dV/dt, vs. ISO= 87±7 dV/dt, 
**p=0.04). Data are presented as mean±SD, n=4-5, p results from two-tailed paired 
Student’s t-tests.  
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excitatory and inhibitory stimuli. We did this by blocking synaptic input with a 
cocktail of neurotransmitter receptor inhibitors. We voltage-clamped the membrane at 
−60 mV and recorded postsynaptic activity in the presence of the inhibitors: 20 µM D-
(-)-2-Amino-5-phosphonopentanoic acid (APV) to inhibit NMDA receptors (Davies 
and Watkins, 1982), 40 µM 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX) to inhibit 
AMPA receptors (Honore et al., 1988), 10 µM strychnine (Stry) to inhibit glycine 
receptors (White, 1985) and 100 µM picrotoxin (PTXN) to inhibit synaptic and 
extrasynaptic GABAA receptors (Alger and Nicoll, 1982). This cocktail blocked large 
depolarizing postsynaptic currents (Figure 8) and inhibited spontaneous firing activity.   
 
 
 
Figure 8. Inhibitors of synaptic ligand-gated channels and receptors block 
synaptic input. Voltage-clamp recording, Vh=−60 mV. Large depolarizing currents 
are blocked by addition of 20 µM AP-V (AMPAR), 40 µM CNQX (NMDAR), 10 
µM Strychnine (Stry; GlyR) and 100 µM Picrotoxin (PTXN; GABAAR). 
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In the absence of spontaneous firing activity, we evoked APs with ramp 
current protocols that slowly increase the membrane potential by injecting steadily 
increasing amounts of depolarizing current. We used these protocols to determine the 
threshold for AP firing and measure the shape of APs evoked using electrical 
stimulation as opposed to synaptic input. Figure 9 shows exemplar traces of APs 
evoked using ramp current injections in control and in the presence of ~1.5 MAC 
FIGURE 9. Isoflurane slows AP velocity, reduces AP amplitude and raises 
threshold of AP firing. Top, Representative traces of APs evoked in the absence 
(left, black) and presence (right, red) of ~1.5 MAC isoflurane using the protocol at 
the top right recorded in the presence of a cocktail of inhibitors of synaptic 
transmission (see Figure 8).  
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isoflurane.  Isoflurane significantly decreased AP amplitude (CTLAP amplitude=79±13 
mV vs. ISOAP amplitude=63±7 mV, n=5, *p=0.02, two-tailed paired Student’s t-test), 
decreased the velocity of the AP upstroke (CTLAP velocity= 35±4 dV/dt, vs. ISOAP 
velocity= 18±6 dV/dt, n=4, mean±SD, **p=0.009, two-tailed paired Student’s t-test) and 
shifted the threshold for AP firing in a depolarizing direction (CTLAP threshold=−28±5 
mV vs. ISOAP threshold=−24±4 mV, n=5, mean±SD, **p=0.004, two-tailed, paired 
Student’s t-test). These results parallel the effects of isoflurane seen on spontaneous 
APs (Figure 7) yet the the amplitude and upstroke velocity of evoked APs are much 
smaller than spontaneous APs. This may be  because excitatory input is blocked 
leaving the dendrites and soma hyperpolarized and able to act as a sink for the current 
generated by the AP. While this truncates the APs, the effect of isoflurane remains and 
further supports a role for block of presynaptic Nav in hippocampal neurons. 
 
Isoflurane blocks endogenous hippocampal Nav at clinical concentrations 
 To directly measure isoflurane effects on Nav, we recorded whole-cell INa from 
hippocampal neurons in the absence and presence of ~1.5 MAC isoflurane. We used a 
Cs+-based internal pipet solution to eliminate outward K+ currents. Whole-cell INa was 
recorded in the voltage-clamp configuration with the membrane potential clamped at 
−70 mV and depolarized to 0 mV for 5 ms to open Nav. Nav exhibited fast activation 
and inactivation kinetics on the millisecond time scale (Figure 10). Addition of ~1.5 
MAC isoflurane reduced peak INa ~10%, similar to previous reports (CTL= −2.7±0.9 
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nA vs. ISO= −2.3±1.1 nA, n=6, mean ± SD, *p=0.04, two-tailed paired Student’s t-
test).  
 
 
 Isoflurane blocks Nav in a voltage-dependent manner (Ouyang et al., 2003; 
Shiraishi and Harris, 2004). We therefore investigated block of Nav by isoflurane 
during repetitive high-frequency stimulation as would be seen in fast-firing neurons 
using trains of 10 5-ms depolarizing pulses at frequencies of 20 – 50 Hz from a 
holding potential of −70 mV (Figure 11A). In order to measure the activity-dependent 
block by isoflurane that develops over the course of the stimulus train in the absence 
FIGURE 10. Isoflurane inhibits peak INa of endogenous neuronal Nav. Left, 
Overlaid traces of whole-cell hippocampal neuron INa recorded at physiologic [Na
+] in 
control (CTL, black) or in the presence of ~1.5 MAC isoflurane (ISO, red) using a Cs+-
based internal solution. Inward current was elicited using the protocol at top. Right, 
Peak INa averaged from 6 neurons in control (CTL, −2.7±0.9 nA) and isoflurane (ISO, 
−2.3±1.1 nA). Data are presented as mean±SD, *p=0.04, two-tailed paired Student’s t-
test. 
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of tonic or resting block, peak INa at each pulse was plotted as a fraction of the peak INa 
of Pulse 1. The decrease in current between Pulse 1 and Pulse 10 in control conditions 
is due to accumulation of inactivated channels at high stimulation frequencies, which 
have insufficient time between stimuli to fully recover from inactivation at the 
hyperpolarized resting membrane potential. Inhibition of INa was increased at higher 
stimulation frequencies (Pulse10/Pulse1: 20 Hz=0.90±0.03, 50 Hz=0.64±0.02, 
mean±SD, n=5-6) (Figure 11B). Addition of ~1.5 MAC isoflurane further enhanced 
this inhibition at stimulation frequencies of 20 Hz (CTLPulse10/Pulse1= 0.90±0.03 vs. 
ISOPulse10/Pulse1= 0.85±0.03, n=6, mean±SD, ***p=0.0005, two-tailed paired Student’s 
t-test) and 50 Hz (CTLPulse10/Pulse1= 0.64±0.02 vs. ISOPulse10/Pulse1= 0.54±0.03, n=5, 
mean±SD, **p=0.006, two-tailed paired Student’s t-test) (Figure 11B).  
We quantified the fraction of block at each pulse due to isoflurane and 
independent of inactivation to compare block by isoflurane at different stimulation 
frequencies. We divided the inhibition of current resulting from isoflurane block 
together with accumulation of inactivation (Pulsen/Pulse1ISO) by block due to 
inactivation alone (Pulsen/Pulse1CTL) for each pulse of the train (Figure 11C). The 
resultant fractional block due to isoflurane at the 10th pulse of the train (1-
[Pulse10/Pulse1ISO/Pulse10/Pulse1CTL]) was significantly greater at 50 Hz stimulation 
(−0.13±0.05, n=5) compared to 20 Hz (−0.03±0.03, n=6; mean±SD, *p=0.02, two-
tailed unpaired Student’s t-test). This analysis shows for the first time that additional 
block of Nav develops during trains of depolarizing stimuli and the extent of this 
‘activity-dependent’ block is increased at higher stimulation frequencies.  
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FIGURE 11. Block of hippocampal INa by isoflurane is increased at higher 
stimulation frequencies. A) Whole-cell INa recorded from hippocampal neurons in 
control (left) and in the presence of ~1.5 MAC isoflurane using the protocol in inset. 
Dotted lines denote peak INa of Pulse 1. Blue arrows indicate decease in current 
between Pulse 1 and Pulse 10. B) Fraction of peak current at each pulse normalized 
to Pulse 1 for control (open symbols) and isoflurane (filled symbols) stimulated at 20 
Hz (circles) and 50 Hz (triangles). C) Fraction of block attributed to isoflurane [1-
(PulseISO/PulseCTL)] at each pulse for 20 Hz (circles) and 50 Hz (triangles) pulse 
trains. Data are presented as mean±SD, n=6.   
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Isoflurane inhibits Nav1.2R in ND7/23 neuroblastoma cells 
To further investigate the mechanism of action of activity-dependent block, we 
transiently transfected rat Nav1.2 into a neuronal cell line and measured channel gating 
kinetics in the absence and presence of isoflurane. Nav are exceptionally large proteins 
that express well in a neuronal expression system (Herold et al., 2009). We used 
ND7/23 cells which are a hybrid of mouse neuroblastoma and rat dorsal root ganglion 
(DRG) neurons to transiently express a TTX-resistant mutant of the neuronal isoform, 
Nav1.2 (F385S) (Leffler et al., 2005), which we refer to as Nav1.2R. External saline 
solutions contained 250 nM TTX to block endogenous INa in the ND7/23 cells in order 
to isolate Nav1.2R current. Figure 12 shows whole-cell INa from untransfected ND7/23 
cells and cells transfected with Nav1.2R.  
Figure 13 shows whole-cell Nav1.2R currents recorded from ND7/23 cells in 
the absence and presence of ~1.5 MAC isoflurane. Current was evoked by a series of 
voltage steps from −50 to +50 mV and preceded by a 50-ms prepulse to −100 mV to 
relieve channels from inactivation. Isoflurane inhibited peak INa at test potentials of 
−10 to +40 mV [n=7, *p<0.05, two-way (voltage x drug) ANOVA with Sidak’s 
multiple comparisons test], without altering the current-voltage (I-V) relationship; 
maximum INa for both control and isoflurane conditions occurred at pulses to 0 mV 
(Figure 13B).  
To measure effects of isoflurane on the voltage-dependence of channel 
activation, we calculated conductance (G), which describes the open probability of the 
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population of channels at a given voltage by removing the effect of the electrical 
driving force from the peak current (see Materials and Methods).  Normalized 
conductance (G/GMAX) at each voltage step was fit with a Boltzmann function and 
changes in the voltage-dependence of activation were determined by comparing the 
mid-points of the curves. In the presence of isoflurane, there was no change in the 
voltage-dependence of activation (V½act control = −15.3±2.7 mV vs.  V½act isoflurane = 
−15.4±2.0 mV, n=6, n.s.) indicating that voltage-dependent effects of isoflurane are 
not due to changes in channel activation (Figure 13C).  
 
 
FIGURE 12. Expression of functional TTX-resistant Nav1.2 (Nav1.2R) in ND7/23 
neuroblastoma cells. Top, brightfield image (left) and fluorescent detection (right) of 
ND7/23 cells plated on glass coverslips and co-transfected Nav1.2R and eGFP. Scale bar 
in inset. Bottom, ND7/23 whole-cell INa in control (black) and in the presence of 250 
nM TTX (red) in an untransfected cell (left, scale bar = 0.5 nA) and a cell transfected 
with Nav1.2R (right, scale bar = 1 nA). 
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We next investigated the effect of isoflurane on the voltage-dependence of 
inactivation by eliciting currents by depolarization to 0 mV following a 50-ms 
prepulse to voltages ranging from −100 to −20 mV (Figure 14A). The current elicited 
FIGURE 13.  Effects of isoflurane on activation properties of Nav1.2R in ND7/23 
cells. A) Representative whole-cell Nav1.2R current traces in the absence (left) or 
presence (right) of 1.5 MAC isoflurane using the protocol in inset. (B) Normalized 
peak current (INa) plotted against test potential in the absence (CTL) or presence 
(ISO) of isoflurane (mean±SD, n=7, *p<0.05, **p<0.01, ****p<0.0001 compared 
to respective control value by two-way ANOVA). C) Normalized conductance 
(G/Gmax) values (mean±SD, n=7) plotted against the voltage command and fit with 
a Boltzmann function. 
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by the 0 mV step following a given prepulse voltage was normalized to the maximum 
current elicited at 0 mV following the most hyperpolarized potentials where 
inactivation is minimal. This fractional current (INa/INamax) reflects the degree of 
inactivation at each prepulse potential and is referred to as steady-state inactivation. 
When fit with a Boltzmann function, isoflurane shifted the voltage-dependence of 
steady-state inactivation in a hyperpolarizing direction (V½ control = −56±2 mV vs. 
V½ isoflurane = −59±2 mV, n=6, **p=0.008, two-tailed paired Student’s t-test) 
(Figure 14B, C). These data suggest that steady-state levels of inactivated channels are 
greater in the presence of isoflurane compared to control. This results in a reduction of 
peak INa by increasing the fraction of inactivated channels at normal resting membrane 
potentials.  
 
FIGURE 14. Effects of isoflurane on inactivation properties of Nav1.2R in ND7/23 
cells. A) Representative whole-cell Nav1.2R current in the absence (left) and presence 
(right) of 1.5 MAC isoflurane using the protocol in inset (prepulse to −60 mV indicated 
with a dashed line). B) Steady-state fast inactivation for control (CTL) and isoflurane 
(ISO), where INa at 0 mV was normalized to the maximum INa for each condition 
(INa/INamax). Average values (n=6, mean±SD) plotted against the voltage command 
and fit with a Boltzmann function. Dotted line denotes 50% channel availability C) 
Average values for voltage at 50% inactivation for control (CTL) and isoflurane (ISO; 
n=6, ***p=0.002). 
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Activity-dependent block of Nav1.2R by isoflurane 
We predicted that this shift in voltage-dependence of inactivation would result 
in similar progressive inhibition of INa during high-frequency trains of stimuli as we 
saw in primary cultures of hippocampal neurons (see Figure 11). We tested this 
hypothesis using high-frequency trains of depolarizing stimuli to elicit INa in the 
absence of presence of ~1.5 MAC isoflurane (Figure 15A). We normalized INa at each 
pulse to the first pulse of the train (Pulsen/Pulse1) to remove any effect of tonic block 
by isoflurane (Figure 15B). For 5-ms pulses delivered at 50-Hz, from a Vh of −90 mV, 
isoflurane reduced the fraction of current at Pulse10 (Pulse10/Pulse1) from 0.90±0.03 to 
0.85±0.03 (n=6, ***p=0.0009). From a Vh of −70 mV, isoflurane reduced 
Pulse10/Pulse1 from 0.68±0.08 to 0.53±0.11 (n=5, ***p=0.0006) (Figure 15C).  
Block was increased at the more depolarized Vh of −70 mV where steady-state 
levels of channel inactivation are greater than at −90 mV, implicating stabilization of 
the inactivated state as the mechanism of activity-dependent block. This mechanism 
supports our previous observation that with increased stimulation frequency channels 
have less time at hyperpolarized membrane potentials to return to the resting state and 
activity-dependent inhibition increases. To determine whether activity-dependent 
block increases with increased stimulation frequency, we compared data from 50- and 
100-Hz pulse trains. Inhibition of INa was undetectable using 20-Hz pulse trains in our 
heterologous system, presumably because of differences in Nav subunits or Nav 
phosphorylation states compared to endogenous channels expressed in our neuronal 
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cultures. We applied trains of 5-ms pulses at 100 Hz from a Vh of −90 mV in control 
and in the presence of ~1.5 MAC isoflurane and compared these results to the 50 Hz 
pulse trains (Figure 15).  Increasing the stimulation frequency from 50 to 100 Hz more 
than doubled the fractional block by isoflurane at Pulse 10 (50 Hz= 0.058±0.018 vs. 
100 Hz, 0.137±0.034, n=6, **p=0.008) (Figure 16). These results provide additional 
support for stabilization of inactivation as the mechanism of activity-dependent block.  
 
FIGURE 15. Activity-dependent block of Nav1.2R expressed in ND7/23 cells.  A) 
Representative current traces in response to a 50-Hz train of 5-ms depolarizing pulses 
to 0 mV from a Vh of −70 mV in the absence (left) or presence (right) of 1.5 MAC 
isoflurane (protocol in inset).  B) Peak INa elicited by each pulse from a Vh of −70 
mV (triangles, n=5) or −90 mV (circles, n=6) normalized to the first pulse of the 
train (Pulsen/Pulse1). Mean± SD data were fit to a mono-exponential function. C) 
Normalized INa at Pulse10 for each cell in B. Dotted lines denote paired data. 
***p<0.001, by two-tailed, paired Student’s t-test. 
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Isoflurane effects on Nav gating kinetics 
We constructed a simple gating model to test whether stabilization of 
inactivation can account for our experimental observations.  Figure 17 shows a model 
of Nav gating including 3 states: resting (R), open (O), and inactivated (I). We 
assigned rate constants to the forward transitions between these states and measured 
them using different voltage protocols in control and in the presence of isoflurane. If 
isoflurane stabilizes I, we expected to see either an increase in the rate of entry into I 
from O (↑kOI), a decrease in the rate of entry into R from I (↓kIR), or a combination of 
these two effects.  
Figure 16.  Fractional inhibition by isoflurane during 50-Hz or 100-Hz pulse 
trains. Left panel, normalized peak INa at each pulse of a 50-or 100-Hz pulse train in 
the absence (CTL) or presence of 1.5 MAC isoflurane (ISO; n=6). Trains consisted 
of 5-ms pulses to 0 mV from a holding potential of −90 mV. Right panel, fractional 
inhibition by isoflurane at each pulse of a 50- or 100-Hz pulse train (n=6). Data 
presented as mean±SD.  
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We tested this hypothesis by measuring the rate of recovery from inactivation 
to estimate kIR. Peak INa was recorded in response to two 5-ms pulses to 0 mV where 
the duration between the two pulses was varied from 1-100 ms. Data are shown as a 
ratio of Pulse 2:Pulse 1 and plotted against the interpulse interval. Recovery time-
courses were fit with a mono-exponential function in both control and in the presence 
of ~1.5 MAC isoflurane, indicating that channels predominantly entered a single 
‘fast’-inactivated state and not any other ‘slow’-inactivated states. Isoflurane increased 
the time required for full channel recovery at a hyperpolarized Vh of −90 mV (control = 
FIGURE 17.  Gating model for isoflurane inhibition of NaV1.2R involving 
stabilization of inactivation. A) Simple gating model of isoflurane inhibition 
involving resting (R), open (O) and inactivated (I) states. Transitions between states 
are indicated by arrows with associated rate constants.  During activation, channels 
transition from R to O to I, and upon repolarization channels recover to availability 
by transitioning from I to R. Curved arrows identify transitions modulated by 
isoflurane (ISO), which enhances (+) transitions from O to I and slows (-) transitions 
from I to R, together representing I stabilization. 
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3.1±0.6 ms vs. isoflurane = 3.9 ±0.8 ms, n=6, *p=0.04, two-tailed paired Student’s t-
test); this effect was enhanced at more physiological Vh (recovery at −70 mV, control = 
6.9 ±1.1 ms; isoflurane = 9.0 ±1.9 ms, n=7, **p=0.004, two-tailed paired Student’s t-
test) (Figure 18B, C).  
 
 
FIGURE 18. Effects of isoflurane on recovery of Nav1.2R from fast 
inactivation. A) Families of whole-cell Nav1.2R current traces recorded in the 
absence (left) or presence (right) of 1.5 MAC isoflurane and evoked from a Vh of 
−70 mV using a paired-pulse protocol where the duration between two 5-ms pulses 
to 0 mV was varied from 1-100 ms (protocol in inset). B) Normalized peak current 
(Pulse2/Pulse1) plotted against duration of the interpulse interval for control (CTL) 
and isoflurane (ISO) from a Vh of −70 mV (n=7) or −90 mV (n=6). Data are 
presented as mean±SD and fit with a mono-exponential function. C) Time constants 
() determined from mono-exponential fits of data from individual cells in B 
(*p<0.05, **p<0.005; by two-tailed, paired Student’s t-test). 
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We estimated the rate of entry into the inactivated state from the open state 
(kOI) by measuring the rate of macroscopic INa decay during a single pulse to 0 mV 
from a holding potential of −70 mV. We normalized current traces in the presence of 
isoflurane to peak INa of paired control experiments (Figure 19A) and fit the decay 
phases using a double exponential function. The majority of the decay phase (~95%) 
could be described by the fast time constant (), again indicating that channels only 
enter the fast-inactivated state using this protocol. Isoflurane reduced the fast  from 
0.36±0.03 ms in control to 0.33±0.05 ms (n=5, *p=0.04, two-tailed paired Student’s t-
test), indicating kOI is increased in the presence of isoflurane. Isoflurane had little 
effect on the slow time constant (2.11±0.99 for control vs. 2.93±1.67 for isoflurane, 
FIGURE 19. Isoflurane accelerates inactivation in Nav1.2R expressed in 
ND7/23 cells. A) Representative responses to a 5-ms stimulus pulse to 0 mV from a 
Vh of −70 mV for control (CTL) or 1.5 MAC isoflurane (ISO) treated cells 
normalized to the peak of CTL. Inset shows a bi-exponential fit (dashed line) of the 
decay phase for CTL (solid line) and ISO (red line). B) Fast and slow  derived from 
bi-exponential fitting of individual cells in the absence (CTL) or presence (ISO) of 
1.5 MAC isoflurane. Bars represent mean±SD, n=6, *p<0.05, by two-tailed, paired 
Student’s t-test. 
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n=5, n.s.) (Figure 19B). Together with a decrease in kIR, the increase in kOI suggests 
that isoflurane blocks Nav by stabilizing channels in the fast-inactivated state and 
increasing the probability that channels will be inactivated and unavailable for opening 
upon membrane depolarization during high-frequency stimulation.  
 
 
FIGURE 20. Onset of isoflurane inhibition matches the time course of 
inactivation. A) Representative current traces recorded in the absence (left) or 
presence (right) of 1.5 MAC isoflurane using a two-pulse protocol (inset) to 
investigate onset of isoflurane inhibition. From a Vh of −90 mV, cells were 
stimulated with two pulses to 0 mV with the duration of the first pulse varied from 
0.7 – 50 ms. B) Peak INa of the test pulse (Pulse2) normalized to that of the 
conditioning pulse (Pulse1) to yield fractional INa (Pulse2/Pulse1). Mean±SD 
fractional INa (n=8) plotted versus Pulse1 duration. C) Fractional INa (mean±SD, 
n=8) for ISO normalized to that of CTL to determine the onset of isoflurane 
inhibition fitted with a mono-exponential function 
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Onset of isoflurane inhibition matches the time-scale of fast-inactivation  
We investigated the onset of isoflurane inhibition to compare the time course 
to that of fast-inactivation. We used a double-pulse protocol with the duration of the 
first pulse to 0 mV varied from 0.7−50 ms. We used a range of pulse durations that 
typically produce complete channel inactivation (>3 ms). Consequently, the protocol 
briefly (2 ms) returns to Vh to allow partial recovery of fast inactivated and inhibited 
channels (Figure 20A).   
In control conditions, longer Pulse 1 durations reduced fractional INa (Pulse 2 
normalized to Pulse 1), reflecting a growing population of inactivated channels that 
fail to fully recover between pulses. Isoflurane decreased fractional INa for all Pulse 1 
durations relative to control (Figure 20B). To investigate the time course of inhibition 
onset, we normalized the isoflurane response to that of control (Figure 20C). The 
response reached an apparent plateau at around 10 ms and was well fit by a mono-
exponential function with kinetics (=2.4±1.6 ms, AP=0.76±0.04, n=8) comparable to 
fast inactivation.  These findings further support involvement of Nav fast inactivation 
in isoflurane action and the validity of our model that stabilization of fast-inactivation 
underlies activity-dependent block of Nav by isoflurane. 
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CHAPTER FOUR 
DISCUSSION 
 
We have shown here for the first time that isoflurane reduces neuronal 
excitability and produces activity-dependent block of Nav by stabilizing the fast-
inactivated state of the channel. This work investigates a novel mechanism of Nav 
block and supports a role for Nav inhibition in the presynaptic effects of isoflurane. 
Using primary cultures of hippocampal neurons and recombinant rat Nav1.2R, we 
measured activity-dependent block of endogenous neuronal Nav and further 
investigated the underlying kinetic mechanism in a reduced system.  Activity-
dependent block of Nav contributed significantly to overall block during high-
frequency stimulation and could have significant effects on fast-firing neuronal 
networks.  Here we discuss the implications of these findings and how they can be 
interpreted in current theories of anesthetic action.  
 
Effects of isoflurane on neuronal excitability 
We show that concentrations of isoflurane equivalent to those used in the clinic 
reversibly inhibit AP firing of rat hippocampal neurons in culture. VAs have been 
shown to depress excitability of hippocampal neurons at much lower concentrations in 
vitro (Fujiwara 1988). However, since anesthetics perfuse readily through the CNS 
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and are only minimally metabolized, MAC is the assumed concentration of drug at the 
receptor and is the concentration that should be used to measure effects in vitro, 
especially since isoflurane has been shown to have bidirectional effects on cellular 
processes depending on drug concentration (Tachibana et al., 2007).  
The effects of isoflurane on spontaneous firing in cultured hippocampal 
neurons are at least in part due to block of Nav since isoflurane affected AP parameters 
largely determined by Nav. The threshold for AP initiation is determined by the 
density of Nav as well as the subtype of Nav expressed in the AIS (Kole et al., 2008; 
Lorincz and Nusser, 2008; Platkiewicz and Brette, 2010). This could imply that 
isoflurane blocks all Nav isoforms present in the AIS equally, thereby shifting the 
threshold for firing by reducing the effective density of Nav, or could imply that 
isoflurane selectively blocks a particular Nav subtype that activates at more negative 
voltages than the other subtypes present. In rat hippocampal neurons Nav1.2 is highly 
expressed in the proximal region of the AIS while Nav1.6 is concentrated in the more 
distal region where its more negative threshold for activation supports AP initiation in 
the distal AIS (Boiko et al., 2003; Hu et al., 2009; Lorincz and Nusser, 2010). We 
hypothesize that subtype-selective block by isoflurane results from Nav1.6 being more 
sensitive than Nav1.2, which would shift the threshold for AP firing towards the more 
depolarized threshold for Nav1.2 activation. A previous study comparing effects of 1 
MAC isoflurane on Nav1.2 and Nav1.6 currents shows that peak Nav1.6 current (with 
and without β1) is relatively more sensitive to inhibition than Nav1.2 (~36% vs. ~28% 
of peak INa at V½), but the voltage-dependence of inactivation was shifted to similar 
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extents in the two isoforms (~10 mV) (Shiraishi and Harris, 2004). This work was 
done in Xenopus oocytes which are a notoriously poor system for studying channel 
behaior as the composition of the membrane can interfere with channel activity 
(Tammaro et al., 2008). However, it suggests that isoflurane might inhibit Nav1.6 to a 
greater extent than Nav1.2. Changes in Nav1.6 current density, but not Nav1.2 density, 
have been shown to affect the threshold for AP firing in a computational model 
(Platkiewicz and Brette, 2010). Interestingly, Nav1.6 is also essential for maintaining 
temporal resolution of APs in response to incoming stimuli (Osorio et al., 2010). This 
may be relevant to systems-level theories of anesthesia that suggest unconsciousness 
arises through the uncoupling of signals within and between the thalamus and the 
cortex (Hudetz, 2012).   
Computational models show that the threshold for AP firing can also be 
affected by the membrane potential and hyperpolarization of the Kv activation curve 
(Wester and Contreras, 2013). While evidence suggests that VAs modulate Kv at 
clinical concentrations (Bhattacharji et al., 2015; Friederich et al., 2001; Urban and 
Haydon, 1987), the majority of evidence shows that VAs inhibit Kv while one study 
suggests VAs enhance activation of  Kv (Barber et al., 2011). The latter study was 
done using sevoflurane on a Drosophila homolog of mammalian Kv3 channels, and 
may reflect agent-specific or Kv subtype-specific effects, whereas the predominant Kv 
subtypes expressed in the AIS of hippocampal neurons are Kv1.1 and Kv1.2 (Lorincz 
and Nusser, 2008; Van Wart et al., 2007). Other candidate channels that could supply 
outward IK to shift the threshold for AP firing are K2P channels, that are known 
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targets of VAs (Franks and Lieb, 1988)(Franks and Lieb, 1988). These channels affect 
resting membrane potential, but since they are not gated, the flow of current through 
them could presumably be controlled by maintaining a steady membrane potential by 
injecting current.   
Our proposal that activity-dependent block affects overall excitability of the 
neuron is supported by evidence that the degree of Nav inactivation modulates 
neuronal excitability and the threshold for AP firing in computational models (Wester 
and Contreras, 2013). Nav inactivation can be modulated by phosphorylation by a 
number of protein kinases and phosphatases (Scheuer and Catterall, 2006). Regulation 
of Nav by PKC has been shown to affect neuronal excitability (Carr et al., 2002), and 
there is evidence to suggest that PKC itself can be a target of VAs (Gomez et al., 
2003; Hemmings and Adamo, 1994).  This poses the question of whether Nav-
dependent anesthetic effects reflect modulation of the channel itself or indirect effects 
on PKC or other modulatory proteins. However, our analysis of the onset of isoflurane 
block of Nav1.2 shows that drug effects are complete within 10 ms, which is on the 
time-scale of inactivation and indicates direct effects on this channel rather than 
modulation through second messengers. Our findings support the hypothesis that 
isoflurane inhibits neuronal excitability through direct actions on neuronal Nav that 
enhance fast-inactivation.  
   
Isoflurane effects on the presynaptic AP and neurotransmitter release 
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We show that clinical concentrations of isoflurane alter the shape of the AP, 
which can affect synaptic transmission and thereby neuronal activity by altering 
neurotransmitter release (Kole et al., 2007; Wu et al., 2004). Isoflurane has been 
shown to preferentially depress exocytosis of glutamate compared to GABA 
(Westphalen and Hemmings, 2003), which can result in relative increases in inhibitory 
GABAergic signalling that would depress firing of pyramidal neurons. VAs have also 
been shown to  increase activity of inhibitory neurons by increasing activity of 
GABAA receptors(Nishikawa and MacIver, 2001) (Nishikawa and MacIver, 2001), 
which could result in an overall depression of activity in neuronal cultures. To 
minimize possible neurotransmitter receptor effects and direct effects on GABAA 
receptors or other major transmitter receptors, we measured APs evoked by electrical 
stimulation in pharmacologically isolated neurons. The amplitude of the AP is 
determined by coordinated opening of Nav and Kv, so effects on either could underlie 
the reduction in amplitude caused by isoflurane. Additional evidence for effects on 
Nav come from the decrease in the maximum velocity of the AP upstroke, which is 
determined by the number of open Nav (Bean, 2007), and the rise in AP threshold, 
which is determined by the voltage-sensitivity and density of Nav (Kole et al., 2008; 
Rush et al., 2005). Our results point to a presynaptic mechanism of action involving 
Nav that occurs independently of GABA-mediated effects which could reduce 
presynaptic excitability and lead to suppression of neurotransmitter release.  
 Isoflurane raised the threshold for AP firing to more depolarized membrane 
potentials. This could affect neuronal excitability by increasing the failure rate for AP 
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initiation. This could manifest in the axon as decreased sensitivity of a neuron to 
excitatory stimuli or could cause AP propagation failure at axonal branch points. In 
dendrites, a higher threshold for Nav activation could lead to early attenuation of APs 
backpropagating from the AIS that works as a feedback mechanism to fine-tune 
incoming stimuli (Jung et al., 1997).  
 
Activity-dependent block of neuronal Nav 
Neuronal signals are transmitted via trains of APs, so activity-dependent block 
of INa is a potentially important mechanism of VA action on neuronal networks. 
Increased block of Nav at higher stimulation frequencies could contribute to network 
selectivity of anesthetic effects. The activity-dependence of block could lead to greater 
sensitivity to isoflurane in fast-firing neuronal networks. By analogy with use-
dependent block by local anesthetics, VAs preferentially inhibit more active neurons 
to selectively suppress fast firing networks (Stewart et al., 1988; Wildsmith et al., 
1989). Small reductions in INa can produce significant effects on oscillatory activity in 
neuronal networks (Arhem et al., 2003) and so, in fast firing networks, the presence of 
isoflurane could have significant and selective effects on neuronal activity.   
Previous assessments of the role of Nav inhibition by general anesthetics in 
vitro have not considered the impact of activity-dependent block, which significantly 
enhances the efficacy of isoflurane inhibition of neuronal Nav under physiological 
conditions. For example, the magnitude of tonic INa inhibition by clinical 
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concentrations of isoflurane is relatively modest: we observed ~10% reduction of peak 
INa, which was comparable to previous reports (Ouyang and Hemmings, 2007; Ouyang 
et al., 2009; Rehberg et al., 1996; Shiraishi and Harris, 2004). In comparison, we 
observed an additional ~20% block at 50-Hz stimulation from a physiological Vh of 
−70 mV. Even modest block of Nav can strongly affect neuronal transmission, as 
small reductions in peak INa alter both frequency of AP firing and neurotransmitter 
release (Wu et al., 2004).   
While the relative sensitivity of the major neuronal isoforms to activity-
dependent block by isoflurane remains to be studied, Nav1.6 expressed in Xenopus 
oocytes is potentiated by repetitive firing (Zhou and Goldin, 2004) and does not show 
activity-dependent depression due to accumulation of inactivated channels. Thus 
Nav1.6 would not be predicted to show the same response to isoflurane as Nav1.2, 
which we show is inhibited at higher stimulation frequencies. However, the shift in AP 
firing threshold may indicate subtype-specific effects on Nav1.6, since Nav1.2 current 
density does not affect AP firing threshold (Platkiewicz and Brette, 2010). The 
subcellular localization of Nav subtypes that differ in their responses to activity-
dependent block can be used as a way to regulate different processes within the same 
cell. Enhanced sensitivity of Nav1.6 peak current to isoflurane (Shiraishi and Harris, 
2004) may alter the AP threshold at the AIS which would regulate the overall 
excitability of the neuron whereas activity-dependent block of Nav1.2 can serve as a 
mechanism to fine tune responses to incoming stimuli in dendrites or to regulate 
neurotransmitter release dependent on the activity of specific boutons.  
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Although the molecular details underlying our proposal that isoflurane 
stabilizes the fast-inactivated state are beyond the scope of the current investigation, 
the mechanism could involve isoflurane binding to a freely accessible receptor that 
allosterically modulates free energy profiles to stabilize the fast-inactivated state.  
Isoflurane can participate in hydrogen bonding by forming dipoles, and has been 
shown to bind hydrophobic macromolecules (Zhang and Johansson, 2005) as well as 
human serum albumin (Eckenhoff et al., 2000). Consistent with this possibility, VA 
binding has been demonstrated in prokaryotic voltage-gated ion channels (Nury et al., 
2011; Spurny et al., 2013), and molecular dynamics simulations of a homology model 
of the bacterial channel NaChBac revealed a possible pathway for isoflurane to enter 
the pore via hydrophobic side fenestrations (Payandeh et al., 2011; Raju et al., 2013). 
Further structural and molecular dynamics studies are necessary to determine where 
isoflurane binds and what residues are involved in stabilizing the bound state of the 
channel. 
 
Conclusions and future directions  
We show that isoflurane stabilizes the fast-inactivated state of neuronal Nav 
such that recovery from fast inactivation is delayed and entry into fast inactivation is 
accelerated, resulting in activity-dependent inhibition. This enhanced inactivation 
leads to progressive inhibition of INa with high-frequency stimulation and contributes 
significantly to overall inhibition of INa by isoflurane through activity-dependent 
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inhibition compared to tonic inhibition. At high stimulus frequencies, Nav inhibition 
by isoflurane and probably other anesthetics that exhibit state-dependent inhibition 
will be greater than that suggested by previous studies of resting block alone.  
Future studies investigating the physiological relevance of activity-dependent 
block by VAs will focus on three areas: 1) effects on the presynaptic AP waveform 
and exocytosis; 2) effects on backpropogation of APs into the dendrites and stimulus 
integration; and 3) relative effects on different Nav subtypes.  
To study the effect of activity-dependent block on the presynaptic AP and 
exocytosis, live-cell imaging of voltage-sensitve fluorescent biosensors could record 
effects of isoflurane on the AP waveform at the bouton. Conventional 
electrophysiology techniques cannot readily access small subcellular structures, but 
recent advances in live-cell imaging techniques revealed that the AP at the bouton has 
a different waveform than the AP in the soma (Hoppa et al., 2014), reflecting a 
different ion channel profile. The AP at the bouton directs Ca2+ influx and 
neurotransmitter release, and so it is important to measure changes in AP waveform to 
understand anesthetic effects on exocytosis. We will use a fluorescently labelled 
synaptic vesicle protein to identify boutons and a voltage-sensitive fluorescent dye to 
image the AP (Hoppa et al., 2014). Electrical stimuli can then be applied at various 
stimulation frequencies to measure the effects of activity-dependent block by 
isoflurane on the bouton AP.    
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Future experiments will also analyse the role of the major Nav subtypes 
expressed in human brain (Nav1.1, Nav1.2, Nav1.3 and Nav1.6) on neuronal 
excitability and sensitivity to activity-dependent block by isoflurane. In this study we 
used rat neonatal hippocampal neurons that demonstrate a pyramidal-like morphology 
and presumably express Nav1.2 and Nav1.6 as the major Nav subtypes. To compare 
Nav subtype-specific differences in sensitivity to isoflurane, we will transfect TTX-
resistant clones into neonatal hippocampal neurons and use TTX to inhibit endogenous 
Nav. We can then compare the sensitivities of specific Nav subtypes to isoflurane and 
their roles in AP firing frequency and AP waveform, activity-dependent block, and 
exocytosis. To determine whether activity-dependent block plays a role in regulating 
exocytosis, we can compare the relative sensitivities of Nav subtypes to activity-
dependent block with the relative sensitivities of Nav subtype coupled to 
neurotransmitter release. This analysis of TTX-resistant Nav subtypes will also provide 
insight into the specialization of function of Nav in excitatory vs. inhibitory neurons. 
While excitatory neurons mainly express Nav1.2, Nav1.3 (in humans) and Nav1.6 
(Goldin, 2001), Nav1.1 has been found exclusively in GABAergic inhibitory neurons 
(Lorincz and Nusser, 2008). We hypothesize that Nav subtype expression profiles 
underlie the different responses to VAs of these two cell types.  VAs preferentially 
inhibit the exocytosis of glutamate (Westphalen and Hemmings, 2003), and this could 
be explained by inhibition of the major excitatory Nav isoforms Nav1.2 and Nav1.6 and 
relative insensitivity of Nav1.1.    
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Future experiments will also investigate whether activity-depedent effects of 
isoflurane lead to increased potency for fast-firing neurons. Nav are essential proteins 
in all excitable cells, yet anesthetic effects arise from specific regions of the CNS. 
Cell-type dependent effects based on the firing-frequency of the neuron can help 
explain the specificity of anesthetic effects. These experiments can be performed in a 
rat preparation such as for the vagus nerve that allows access to A, B, and C fibers that 
fire at different frequencies (Wildsmith et al., 1989) to measure the relative 
sensitivities of each nerve fiber at clinical concentrations of isoflurane.  
The specificity of VAs for the particular regions of the CNS that give rise to 
anesthesia remains a mystery. Activity-dependent block of Nav by isoflurane suggests 
a novel mechanism for discriminating between different neurons based on firing-
frequency. Inhibition of Nav due to activity-dependent block is relatively modest, but 
small changes in channel kinetics rather than full block of current might contribute to 
the mechanism of anesthesia. This is in keeping with the predictions of Franks and 
Lieb who, based on the immediate onset and ease of reversibility of general 
anesthetics, predicted that the mechanism of action of these drugs would involve only 
small changes to the structure of protein targets and modest changes in their activity 
(Franks and Lieb, 1982).  
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APPENDICES 
 
The appendices include work done in Geoffrey Abbott’s laboratory  at Weill 
Cornell Medical College. I investigated the role of voltage-gated K+ channel β 
subunits belonging to a family of single transmembrane proteins encoded by the 
KCNE genes. We found that these proteins, known as ‘MiRPs’ and originally 
discovered in  the excitable cells of the heart, are essential in the proper functioning of 
the epithelial lining of the stomach, thyroid and choroid plexus. KCNE2 and KCNE3, 
also known as Mirp1 and Mirp2, respectively, convert the voltage-activated KCNQ1 
K+ channel into a voltage-insensitive leak channel that passes K+ through the 
membrane of electrically silent epithelial cells and supports acidification of the 
stomach lumen, production of thyroid hormone and ionic homeostasis of the cerebral 
spinal fluid.   
This work used positron emission tomography to show that KCNE2 is 
essential for the uptake of iodide into the thyroid and we proposed the KCNE2 gene as 
an underlying link between thyroid dysfunction and heart disease. We also 
investigated the role of KCNE2 in the stomach where it is essential for gastric acid 
secretion. After finding upregulation of KCNE3 in the stomach of KCNE2 knock-out 
mice, we generated a KCNE3 knock-out mouse line and bred KCNE2/KCNE3 double 
knock-out mice to study the effects of these subunits on the trafficking and function of 
the KCNQ1 channel in the stomach.  
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Abstract 
The KCNQ1 α subunit and the KCNE2 β subunit form a potassium channel in thyroid 
epithelial cells. Genetic disruption of KCNQ1-KCNE2 causes hypothyroidism in 
mice, resulting in cardiac hypertrophy, dwarfism, alopecia, and prenatal mortality. 
Here, we investigated the mechanistic requirement for KCNQ1-KCNE2 in thyroid 
hormone biosynthesis, utilizing whole-animal dynamic positron emission tomography. 
The KCNQ1-specific antagonist (−)-[3R,4S]-chromanol 293B (C293B) significantly 
impaired thyroid cell I− uptake, which is mediated by the Na+/I− symporter (NIS), in 
vivo (dSUV/dt: vehicle, 0.028±0.004 min−1; 10 mg/kg C293B, 0.009±0.006 min−1) and 
in vitro (EC50: 99±10 μM C293B). Na+-dependent nicotinate uptake by SMCT, 
however, was unaffected. Kcne2 deletion did not alter the balance of free vs. 
thyroglobulin-bound I− in the thyroid (distinguished using ClO4
−, a competitive 
inhibitor of NIS), indicating that KCNQ1-KCNE2 is not required for Duox/TPO-
mediated I− organification. However, Kcne2 deletion doubled the rate of free I− efflux 
from the thyroid following ClO4
− injection, a NIS-independent process. Thus, 
KCNQ1-KCNE2 is necessary for adequate thyroid cell I− uptake, the most likely 
explanation being that it is prerequisite for adequate NIS activity.
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Introduction 
Potassium ion (K+) channels provide a K+-selective aqueous pore for the diffusion of 
K+ across the plasma membrane, and are essential for function of most if not all 
mammalian cell types.  Voltage-gated potassium (Kv) channels are gated (opened and 
closed) by changes in membrane potential.  They are opened by membrane 
depolarization and are essential for the timely repolarization of excitable cells. Other 
K+ channels are constitutively active, i.e., open at resting membrane potential.  
Defining the role of constitutively active K+ channels in vivo can be challenging: they 
contribute an often temporally invariant ‘background’ K+ conductance, and may be 
expressed in cell types resistant to faithful primary culturing or direct 
electrophysiological analysis.  In addition, constitutively active K+ channels in 
particular may be important for processes difficult to quantify in vivo or in vitro, 
including ion homeostasis, and hormone synthesis and release. 
The KCNQ1-KCNE2 potassium channel has an unusual molecular 
composition for a constitutively active K+ channel, but is widely studied because its 
subunits are required for a range of processes essential in human physiology.  The 
KCNQ1 pore-forming (α) subunit contains the S4-based voltage-sensing domain 
present in voltage-gated K+, Na+ and Ca2+ channels.  However, while homomeric 
channels formed by a tetramer of KCNQ1 α subunits are voltage-gated, heteromeric 
channel complexes comprising KCNQ1 together with the single-transmembrane 
segment KCNE2 β subunit are constitutively active, and relatively voltage-insensitive 
(1).  KCNQ1-KCNE2 channels are essential for the physiology of at least two types of 
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non-excitable, polarized epithelial cells: gastric parietal cells, which secrete gastric 
acid, and thyroid epithelial cells, which secrete thyroid hormones.  Targeted deletion 
of either Kcnq1 or Kcne2 causes both hypothyroidism and achlorhydria, demonstrating 
the absolute necessity for both α and β subunits in the native channel complex (2-6).   
Kcne2-/- mice also exhibit dwarfism, alopecia (Fig. 1A), prenatal mortality and 
cardiomegaly, all of which arise from their underlying hypothyroidism (5); Kcnq1-/- 
mice were also recently found to be hypothyroid (6).  Human KCNQ1 and KCNE2 
gene mutations cause potentially fatal ventricular and atrial cardiac arrhythmias, 
probably primarily due to the role of these subunits in cardiac myocyte K+ currents (7, 
8); however, the discovery of the KCNQ1-KCNE2 channel in mouse and human 
thyroid suggests a possible endocrine component to these electrical disturbances (5).  
Here, we sought to elucidate the mechanistic basis for the requirement for KCNQ1-
KCNE2 channels in thyroid function.  To examine thyroid physiology in vivo, we 
utilized positron emission tomography (PET) to quantitatively image 124I- fluxes in 
mice genetically and pharmacologically manipulated to isolate different steps in 
thyroid hormone biosynthesis.  We demonstrate that KCNQ1-KCNE2 is required for 
Na+/I- symporter (NIS)-mediated thyroid cell uptake of I-, an essential step in thyroid 
hormone biosynthesis. 
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Materials and Methods 
Transgenic mouse generation, care and use 
We generated and genotyped the C57BL/6 Kcne2–/– mouse line as previously 
described (4, 5) and housed and used mice according to the US National Institutes of 
Health Guide for the Care and Use of Laboratory Animals.  Animal procedures were 
approved by the Animal Care and Use Committees at Weill Medical College of 
Cornell University and Albert Einstein College of Medicine. 
 
Positron Emission Tomography (PET) and Computed Tomography (CT) 
Mice were secured to a bed with a breathing tube over their snout that provided a 
continuous supply of isoflurane anesthetic throughout the imaging procedure (Fig. 
1C). Imaging was performed on an Inveon Multimodality scanner (Siemens), in which 
CT x-rays were generated by an 80 kV peak voltage difference between cathode and 
tungsten target at 0.5 mA current and 250 ms exposure time.  The CT field of view 
was 5.5 cm by 8.5 cm with an overall resolution without magnification of 100 µm.  
Subsequent PET imaging was performed by translating the test subject on the imaging 
gantry into the PET device which provided a 12.7 cm axial and 10 cm transaxial active 
field of view.  The PET scanner has no septa and acquisitions were performed in 3D 
list mode.  A reconstructed FWHM resolution of <1.4 mm is achievable in the center 
of the axial field of view.  List mode acquisition of data was performed to permit 
dynamic re-framing for kinetic evaluation of 124I- uptake, where indicated.  After each 
acquisition, data were sorted into 3D sinograms, and images were reconstructed using 
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a 2D-Ordered Subset Expectation Maximization algorithm.  Data were corrected for 
deadtime counting losses, random coincidences and the measured nonuniformity of 
detector response (i.e., normalized) but not for attenuation or scatter. After both 
acquisitions, CT images were coregistered with PET images using a previously stored 
linear transformation matrix. 
Analysis was performed using ASIPRO (Siemens) dedicated software. All 
image studies were inspected visually in a rotating 3D projection display to examine 
for interpretability and image artifact. Manual regions of interest (ROI) were defined 
around the thyroid.  Successive scrolling through 2 dimensional slices (each 1.2 mm 
thick in the axial images) permitted measurement of a radioactivity within defined 
volumes, and also as profiles in reconstructed image planes. The counts per cc within 
this volume multiplied by the 3D ROI volume after correction for detector sensitivity, 
animal weight, and time of injection determined the standardized-uptake value (SUV).   
 
Methimazole (MMI) treatment  
Mice were given an intraperitoneal (i.p.) injection of 1 mg MMI (Sigma-Aldrich, St. 
Louis, MO, USA) in 100 µl total volume filter-sterilized PBS, and overnight ad 
libitum access to drinking water containing 250 mgl-1 MMI.  
 
Perchlorate Discharge Assay  
Lactating or aging dams, anesthetized with 1.5% isoflurane-oxygen mixture, received 
200-300 µCi (7-12 MBq) 124I- in 0.1 ml saline solution via tail-vein injection.  Dams 
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were placed back in their cages for 90 minutes to allow accumulation of the 124I- tracer 
in the thyroid, then imaged for 10 minutes before, and for the 60 minutes following, 
injection of 2 mg sodium perchlorate (NaClO4, Sigma Aldrich) in a total volume of 
0.1 mL PBS via tail vein.  Measurements of thyroid counts taken at 5 minute intervals 
following NaClO4 injection were normalized to the maximum count value taken from 
the pre-ClO4
- image.  
 
Uptake experiments  
Stock solutions of 80 mM (-)-[3R,4S]-chromanol 293B (Tocris Biosciences, 
Cambridge, UK) dissolved in pure DMSO were prepared and stored at -20ºC.  The 
stock was diluted to a final concentration of 2.5 mg ml-1 in PBS with 20% DMSO. 
Vehicle controls contained 20% DMSO in PBS. Mice were injected with 0.1 ml of 
drug or vehicle 30 minutes before injection with 124I- (150 µCi, 5.55 MBq) dissolved 
in 0.1 ml saline. 
 
Cell culture, transport, and flow cytometry experiments  
FRTL5 cells were grown in Coon’s modified Ham’s F12 medium supplemented with 
5% newborn calf serum (Sigma Aldrich) and 6 different hormones (insulin 10 mg ml-
1, transferrin 5 mg ml-1, hydrocortisone 10 nM, tripeptide Gly-L-His-L-Lys 10 ng ml-1, 
TSH 0.3 mU ml-1, and somatostatin 10 ng ml-1) in a water-saturated atmosphere of 5% 
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CO2 and 95% air at 37C.  For transport assays, FRTL5 cells were cultured on 24-well 
plates.  
Uptake experiments were initiated by adding 500 μl HBSS (137 mM NaCl, 5.4 
mM KCl, 1.3 mM CaCl2, 0.4 mM MgSO4, 0.4 mM Na2HPO4.7H2O, 0.44 mM 
KH2PO4, and 0.55 mM glucose), buffered with 10 mM Hepes-KOH (pH 7.5) 
containing 20 μM Na125I- (Perkin Elmer, Wellesley, MA, USA) with a specific activity 
of 50 Ci/mol, in the presence or absence of (-)-[3R,4S]-chromanol 293B.  FRTL5 cells 
were incubated at 37˚C in a humidified atmosphere for 30 min. Reactions were 
terminated by aspirating the radioactive solution and washing three times with HBSS.  
Accumulated 125I- was determined by permeabilizing cells with ethanol for 20 minutes 
and quantifying the released radioisotope in a gamma counter.  Data were standardized 
per μg of DNA in each well. Concentration of DNA was assessed by the 
diphenylamine method (9).  [14C]nicotinate (Moravek Biochemicals, Brea, CA, USA) 
uptake was measured using the same procedure, except that cells were incubated with 
buffered HBSS containing 50 μM [14C]nicotinate.  NaCl was replaced with equimolar 
concentrations of choline chloride to determine the Na+ dependence of SMCT-
mediated nicotinate transport.  
For flow cytometry, FRTL-5 cells were transduced with extracellular N-
terminal hemagglutinin (HA)-tagged human NIS, as described previously (11). 
Paraformaldehyde-fixed cells were incubated in PBS containing 0.2% BSA with 3 nM 
anti-HA (clone 3F10) rat monoclonal IgG (Roche Applied Science, Mannheim, 
Germany). The fluorescence of 2 × 104 cells/tube was assayed in FACSCalibur flow 
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cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed with FlowJo 
software (Tree Star, Ashland, OR, USA). 
COS-7 cells were grown in DMEM supplemented with 10% heat-inactivated 
FBS (Sigma-Aldrich). Cells were transfected with 10 μg/10-cm dish pcDNA3.1-rNIS 
or -hNIS cDNA constructs using polyethylenimine. I− uptake activity was assayed at 
48 h post-transfection. 
 
Results 
PET imaging of a chemically induced iodine organification defect in mouse thyroid. 
We previously utilized PET imaging to discover that Kcne2 deletion in mice impairs 
thyroid 124I- accumulation (5).  Here, we combined PET with other techniques to 
determine the underlying mechanism for this impairment.  Thyrocytes actively take up 
I- via the basolateral Na+/I- symporter (NIS) (10).  I- next effluxes across the thyrocyte 
apical membrane to the cell-colloid interface, where it is oxidized and covalently 
incorporated into specific tyrosyl residues on thyroglobulin – a process termed 
‘organification’ and catalyzed by thyroid peroxidase (TPO) and the NADPH-
dependent H2O2-generating system (Duox) (Fig. 1 B).  Iodinated thyroglobulin (Tg) is 
then stored in the colloid until demand for thyroid hormones causes Tg to be apically 
endocytosed and proteolyzed, and thyroid hormones to be basolaterally secreted into 
the bloodstream (11, 12). To establish the mechanism for impaired thyroid 124I- 
accumulation in Kcne2-/- mice, we needed to distinguish between free I- and iodine 
covalently incorporated into Tg, and also between I-  uptake and iodine organification.  
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Figure 1. PET quantification of ClO4
−-induced 124I− discharge in MMI-treated 
mice. A) Age-matched 3-wk old Kcne2+/+ and Kcne2-/- pups bred from same-genotype 
dams, showing dwarfism and alopecia in the latter. B) Schematic of I− uptake and 
organification in the thyroid. C) Exemplar coregistered PET-CT image of a 6-mo-
old Kcne2+/+ mouse, injected with124I− and positioned in the anesthesia-delivery nose 
cone. Heat map (scale at right) for PET image shows positioning of the thyroid (t), 
stomach (s), and bladder (b). CT bony structures are evident in purple color scale. D) 
Schematic showing experimental protocol for validating PET imaging of ClO4
−-induced 
I− discharge, using MMI-pretreated mice. E) Exemplar pre- and post-ClO4
− PET images 
for an MMI-pretreated Kcne2+/+ mouse (protocol in D; 150 μCi of 124I− injected). 
Tissues labeled as in C. Scale bar at right. F) Mean thyroid counts normalized to pre-
ClO4
− thyroid counts for MMI-pretreated Kcne2+/+ mice, demonstrating ClO4
− -
induced 124I− discharge (protocol in D; n=5). Error bars = SEM. 
 
 
First, we employed co-registered PET and X-ray computed tomography (CT) 
on mice tail-vein-injected with 124I, to confirm positioning of the thyroid signal 
compared to other I--accumulating tissues such as the stomach and bladder (Fig. 1 C).  
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We then sought to determine whether or not KCNQ1-KCNE2 is required for thyroid I- 
organification, using PET in combination with the well-established perchlorate (ClO4
-) 
discharge assay (PDA).  ClO4
-, a competitive inhibitor of NIS, that is translocated 
electroneutrally (13) causes a rapid reduction of free I- in the thyroid (as I- can efflux 
from but not enter the thyrocyte in its presence).  When organification is normal, ClO4
- 
elicits only moderate thyroid I- discharge (~15%) because most I- is rapidly covalently 
bound to Tg, whereas an organification defect can result in a ClO4
--induced I- 
discharge of 50% or more (14).   
We first assessed the suitability of PET for quantifying ClO4
- discharge in the 
mouse thyroid, by ascertaining the effect of pretreating ‘wild-type’ C57BL/6 mice 
with methimazole (MMI), a thionamide that blocks I- organification by inhibiting TPO 
(15, 16).  MMI pretreatment involved an intraperitoneal (i.p.) injection of MMI, 
followed by overnight ad libitum access to water supplemented with MMI.  The 
following day, 90 minutes after tail vein injection of 124I-, a 10 min static PET image 
was generated to measure peak 124I- accumulation.  Mice immediately received ClO4
- 
via tail-vein injection and were PET-imaged dynamically at 5 minute intervals for 60 
minutes (Fig. 1 D, E). Mean thyroid radioactivity at each 5 minute interval following 
ClO4
- injection was normalized to the mean pre-ClO4
- thyroid radioactivity to quantify 
discharge.  ClO4
- resulted in a 45 ± 4% discharge of 124I within the first hour after 
injection in MMI-pretreated mice, thereby confirming successful detection of the 
chemically induced organification defect and validating the PET assay (n = 5) (Fig. 
1F).   
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Figure 2. Kcne2 deletion does not cause an I– organification defect. A) Schematic 
showing experimental protocol for PET quantification of ClO4
− -induced I− discharge 
in Kcne2+/+ and Kcne2−/− mice. B) Exemplar pre- and post-ClO4
− PET images 
for Kcne2+/+ and Kcne2−/− mice (protocol in A). Labeled tissues: thyroid (t), stomach 
(s), and bladder (b). Scale bar at right. C) Mean thyroid counts normalized to pre-ClO4
− 
thyroid counts for Kcne2+/+ and Kcne2-/- mice as in B, compared to data for MMI-
pretreated Kcne2+/+ mice (data from Fig. 1F); n = 5 mice/group. Error bars = SEM. *P < 
0.0005 vs. non-MMI-pretreated mice, 60-min time point. 
 
 
KCNQ1-KCNE2 is not required for I- organification 
We next quantified the effect of targeted deletion of Kcne2 on ClO4
--induced 
discharge of thyroid I- in non-MMI-treated lactating C57BL/6 mice using PET, 
following the protocol outlined in Fig. 2 A, and observed 19 ± 3% discharge within 
the first hour after injection in Kcne2+/+ mice compared to 14 ± 4% in Kcne2-/- mice (n 
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= 5; P = 0.19) (Fig. 2 B, C).  There was therefore no significant effect of Kcne2 
deletion on organification.  Furthermore, both non-MMI-pretreated groups exhibited 
significantly less discharge than MMI-pretreated Kcne2+/+ mice (n = 5; P < 0.0005) 
(Fig. 2 C).  Lactating mice were used for these experiments because hypothyroidism in 
Kcne2-/- mice is most marked during early development, gestation, lactation, and in 
old age (5). 
 
KCNQ1-KCNE2 is required for efficient I- uptake 
The absence of an organification defect in Kcne2-/- mice, combined with our previous 
finding that Kcne2 deletion impairs thyroid I- accumulation (5), suggested KCNQ1-
KCNE2 could be important for NIS-mediated I- uptake.  To test this hypothesis, we 
first used the highly specific KCNQ1 antagonist (-)-[3R,4S]-chromanol 293B (C293B) 
to acutely inhibit KCNQ1-KCNE2, in Kcne2+/+ mice pretreated with MMI to inhibit 
organification, allowing us to assess I- transport at steady state.  This approach 
dissociated the uptake process from 124I- organification, eliminating radiolabeling of 
Tg and thus facilitating exclusive imaging of NIS-mediated transport of free 124I- in the 
thyroid.  Following overnight MMI treatment, mice were tail-vein injected with either 
C293B [(10 mgkg-1) or vehicle, then 30 minutes later tail-vein injected with 124I- and 
immediately dynamically PET imaged for 60 minutes to quantify 124I- uptake (Fig. 
3A).  Strikingly, C293B (10 mgkg-1) impaired 124I- by 42% at 60 min, giving a mean 
thyroid radioactivity of 0.69 ± 0.11 SUV (standard uptake value, i.e., counts 
normalized to whole-body mean radioactivity concentration; whole body SUV = 1.00, 
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by definition) compared to 1.18 ± 0.06 SUV in vehicle-injected mice (n = 5; P < 
0.005) (Fig. 3 B,C), signifying 124I uptake and retention. Initial thyroid I− uptake rates 
were reduced 3-fold by C293B (10 mg/kg), with the dSUV/dt being reduced from 
0.028 ± 0.004 min−1 (vehicle) to 0.009 ± 0.006 min−1 (C293B; n=5, P=0.014; Fig. 
3D).  
 
 
 
 
Figure 3. Pharmacological inhibition of KCNQ1-KCNE2 impairs thyroid 
I− uptake in vivo. A) Schematic showing experimental protocol for PET quantification 
of the effect of C293B (10 mg/kg) on thyroid 124I− uptake in MMI-
pretreated Kcne2+/+ mice. B) Exemplar PET images for vehicle- or 10 mg/kg C293B-
treated Kcne2+/+ mice, at the indicated times following 124I− injection (protocol in A). 
Labeled tissues: thyroid (t), stomach (s), and bladder (b). Scale bar at right. C) Mean 
thyroid 124I− counts during the first hour following 124I− injection for MMI-
pretreated Kcne2+/+ mice as in B, injected with vehicle or 10 mg/kg C293B 30 min 
before 124I−; n = 5 mice/group. Error bars = SEM. *P < 0.005 vs. vehicle-treated, 60-min 
time point. D) Mean initial (0–13.3 min) thyroid I− uptake rates determined from graphs 
as in C for individual mice, groups as in C; n = 5. *P = 0.014. 
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To validate this finding in an alternative system, we performed 125I- flux assays 
using the highly functional rat thyroid-derived FRTL5 cell line (Fig. 4A), which we 
previously showed expresses KCNQ1-KCNE2 channel protein and K+ current (5).  
FRTL5 cells exhibit minimal I- organification, but express NIS and efficiently 
transport I-.  Increasing concentrations of C293B inhibited NIS-mediated I- uptake in a 
dose-dependent manner (EC50: 99±10 μM C293B; n=4; Fig. 4B); in contrast, they did 
not affect another Na+-driven transport process, namely SMCT-mediated nicotinate 
uptake (Fig. 4B), demonstrating the specificity of the inhibition of I- uptake and also 
indicating that impaired NIS function arising from KCNQ1-KCNE2 inhibition does 
not stem from a disrupted Na+ gradient. In support of the KCNQ1-dependence of 
action of C293B, it did not inhibit cell-surface expression of HA-tagged NIS in FRTL-
5 cells, as quantified by flow cytometry, indicating that the decrease of I− uptake 
caused by C293B is not due to fewer NIS molecules at the plasma membrane (Fig. 
4C). Likewise, C293B had no effect on I− uptake through rat or human NIS when 
heterologously expressed, without KCNQ1 overexpression, in COS-7 cells (Fig. 4D). 
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Figure 4. Pharmacological inhibition of KCNQ1-KCNE2 specifically impairs 
I− uptake in vitro. A) FRTL-5 cell simplified model to illustrate various key ion 
fluxes. AC, anion channel; E2, KCNE2; Q1, KCNQ1; Nic−, nicotinate; NIS, Na+/I− 
symporter; SMCT, sodium/monocarboxylate transporter. B) C293B inhibition of 
125I− steady-state uptake by FRTL5 cells (red squares) for various C293B 
concentrations. Values were normalized to steady-state uptake of 125I− by FRTL5 
cells bathed in DMSO as a vehicle control. Data are means of 4 independent 
experiments/concentration, each performed in triplicate. 125I− uptake values in the 
presence of ClO4
− were <3.7% (data not shown). Dose response was fitted with a 
sigmoidal function. Also shown: [14C]nicotinate steady-state uptake in FRTL-5 
cells bathed in medium containing 50 μM [14C]nicotinate, and either Na+ (green 
circles) or choline (blue triangles), to assess effects of C293B on the function of 
SMCT. C) FRTL-5 cells expressing extracellular HA-tagged NIS were incubated 
with 100 μM C293B or vehicle for 1 h. Histograms indicate NIS expression at the 
plasma membrane quantified by flow cytometry using an anti-HA antibody under 
nonpermeabilized conditions (left) or permeabilized conditions as a control for total 
protein (right). Unstained control cells in red, DMSO-treated cells in cyan, and 
C293B-treated cells in orange. Data are representative of 2 experiments, each 
performed in duplicate. D) I− steady-state uptake in rNIS- or hNIS-transfected COS-
7 cells incubated with 20 μM 125I−, 100 μM C293B, or vehicle as indicated, and in 
the absence (red) or presence (blue) of 40 μM ClO4−. Data are representative of 3 
independent experiments, each performed in triplicate. Error bars = SD. 
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Discussion 
After initially being recognized for their respective roles in voltage-dependent K+ 
channels in cardiac myocytes, KCNQ1 and KCNE2 were found to form a 
constitutively active K+ channel (1), subsequently identified in gastric parietal cells (3, 
17).  KCNQ1-KCNE2 recycles K+ from the parietal cell to the stomach lumen, 
facilitating the 1:1 exchange of H+ ions for K+ ions required by the H+/K+-ATPase for 
gastric acid secretion (3, 17, 18).  Thus, genetic disruption of either Kcnq1 or Kcne2 in 
mice causes achlorhydria and gastric hyperplasia owing to an inability to secrete 
gastric acid (2, 4).  Following up on our recent discovery that the KCNQ1-KCNE2 K+ 
channel is important for thyroid hormone biosynthesis (5), we have now utilized PET 
to uncover the mechanistic basis for this requirement: without functional KCNQ1-
KCNE2, I- uptake into the thyroid is impaired, with no direct effect on I- 
organification (Fig. 5).   
The requirement for KCNQ1-KCNE2 for thyroidal I- uptake may indicate that 
KCNQ1-KCNE2 is necessary for adequate function of NIS, the primary thyrocyte I- 
uptake conduit.  This functional requirement almost certainly does not involve a need 
for KCNQ1-KCNE2 to supply the thyrocyte basolateral Na+/K+ ATPase with K+ so 
that it can maintain a Na+ gradient for NIS, because KCNQ1 inhibition did not affect 
function of another Na+-driven transporter, SMCT (Fig. 4B).   
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Figure 5. Summary of effects of KCNQ1-KCNE2 disruption on thyrocyte 
function. A) In the normal thyroid, basolateral uptake through NIS supplies I− for 
apical organification (iodination of Tg) and thyroid hormone biosynthesis. KCNQ1-
KCNE2 is expressed on the basolateral surface. B) Left panel: when KCNQ1-
KCNE2 is pharmacologically inhibited, organification is not directly impaired, but 
I− uptake is reduced, reducing thyroid hormone biosynthesis, while SMCT function 
is maintained. Right panel: Kcne2 deletion also reduces I− uptake without affecting 
organification. Impaired NIS function is the prime candidate, but it is possible that 
Kcne2 deletion also increases I− leak through anion channels, as suggested by an 
increased rate of I− efflux following NIS inhibition by ClO4
−in vivo. 
 
One possible mechanism is that KCNQ1-KCNE2 is required to regulate 
thyrocyte membrane potential in vivo, and that with Kcne2 or Kcnq1 deleted, or the 
channel pharmacologically inhibited, this function is perturbed.  NIS-mediated I- 
uptake is electrogenic, with two Na+ entering for every I-, therefore, its activity would 
depolarize the cell in the absence of other regulatory ion fluxes.  Given that KCNQ1-
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KCNE2 is constitutively active, it has the capacity to permit K+ efflux to help maintain 
a negative membrane potential.  If this channel is pharmacologically blocked (Fig. 
5B), or if the Kcnq1 gene itself is deleted, the thyrocyte could become depolarized, 
and NIS function could therefore be impaired due to a decrease in the membrane 
potential, one of the two components of the electrochemical driving force of NIS. 
Deletion of Kcne2 may have slightly different effects, albeit still resulting in 
impaired thyroid hormone biosynthesis.  We recently found that KCNE2 is expressed 
in the choroid plexus epithelium, where it forms K+ channels with KCNQ1 and with 
Kv1.3 (KCNA3) (19).  When Kcne2 is deleted, choroid plexus epithelial outward K+ 
currents actually increase, because KCNE2 normally partially suppresses Kv1.3 and 
KCNQ1outward currents (although endowing the latter with the ability to remain open 
at very negative potentials).   This hyperpolarizes the choroid plexus cells, and may 
contribute to the higher cerebrospinal fluid [Cl-] we observe in Kcne2-/- mice (19).  It 
is possible that this effect also occurs in the thyroid of Kcne2-/- mice, possibly favoring 
I- loss through nonspecific anion channels.  Significantly, the loss of I- from the 
thyrocyte which is clearly observed following competitive inhibition of NIS with 
ClO4
- occurs via a NIS-independent mechanism, probably through one or more types 
of anion channel and down the I- electrochemical gradient.  Kcne2 deletion doubled 
the rate of this I- efflux (Fig. 2C), and we speculate that thyrocyte I- ‘leak’ arising from 
hyperpolarization in Kcne2-/- mice could contribute to their inability to accumulate I- 
as efficiently as their wild-type counterparts.  Future studies will be aimed at further 
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dissecting the molecular basis of the requirement for KCNQ1-KCNE2 in NIS-
mediated I- uptake.      
In summary, we demonstrate here that state-of-the-art imaging techniques can 
be combined with genetically tractable small animal models, pharmacological tools, 
and in this case a standard clinical assay for organification deficiency (the ClO4
- 
discharge test) to discern physiologically and pathophysiologically important 
mechanisms in vivo.  The discovery of this link between a K+ channel and a plasma 
membrane transporter suggests that similar such links may yet be found in a wide 
variety of cell types.  The findings also present proof-of-principle that 
pharmacological inhibition of KCNQ1-KCNE2 can be used to alter thyroid function – 
opening up potential novel therapeutic avenues for thyroid disorders.  
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Summary 
Inherited Long QT Syndrome (LQTS), a cardiac arrhythmia that predisposes to the 
often lethal ventricular fibrillation, is commonly linked to mutations in KCNQ1. The 
KCNQ1 voltage-gated K+ channel α subunit passes ventricular myocyte K+ current 
that helps bring a timely end to each heart-beat. KCNQ1, like many K+ channel α 
subunits, is regulated by KCNE β subunits, inherited mutations in which also associate 
with LQTS. KCNQ1 and KCNE mutations are also associated with atrial fibrillation. 
It has long been known that thyroid status strongly influences cardiac function, and 
that thyroid dysfunction causes abnormal cardiac structure and rhythm. We recently 
discovered that KCNQ1 and KCNE2 form a thyroid-stimulating hormone-stimulated 
K+ channel in the thyroid that is required for normal thyroid hormone biosynthesis. 
Here, we review this novel genetic link between cardiac and thyroid physiology and 
pathology, and its potential influence upon future therapeutic strategies in cardiac and 
thyroid disease. 
 
1. Introduction 
Excitable cells facilitate dynamic processes such as electrical signaling in the brain 
and rhythmic beating of the heart. Excitability, defined in this context as the ability to 
sustain action potentials, requires voltage-gated sodium (NaV) channels for the 
depolarization phase (upstroke) and voltage-gated potassium (KV) channels for the 
repolarization phase (downstroke) (Fig. 1A). The ventricles of the human heart 
provide most of the contractile force for pumping blood to the lungs and around the 
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rest of the body, and the integrity of the ventricular myocyte action potential is 
therefore crucial for life. Influx of Na+ ions through NaV1.5 (encoded by SCN5A) 
depolarizes human ventricular myocytes, and K+ efflux through a variety of K+ 
channel types, primarily KV channels, facilitates myocyte repolarization. The most 
prominent repolarization phase, Phase 3, is coordinated primarily by two KV α 
subunits: hERG and KCNQ1, which respectively generate the IKr and IKs 
repolarization currents (Fig. 1B). The completion of ventricular repolarization 
manifests on a surface electrocardiogram (ECG) as the end of the T wave (Fig. 1C). 
KCNQ1 and hERG, as with all other KV α subunits, each contain six transmembrane 
helices within which is a voltage sensor that moves upon membrane depolarization – a 
conformational shift transmitted to the channel pore, or gate, which then opens to 
permit ion flux; four KV α subunits are necessary and sufficient to form a functional 
(tetrameric) pore. However, in vivo, hERG and KCNQ1 each form complexes with 
KCNE β subunits, also referred to as MinK-related peptides (MiRPs). KCNE subunits 
are single-transmembrane-segment (TMS) proteins that do not pass current alone, but 
co-assemble with pore-forming KV α subunits to regulate their trafficking, gating, 
conductance, regulation by other proteins, and pharmacology (Fig. 2). Importantly, 
both the KCNE β subunits and the KV α subunits are promiscuous, helping to create 
K+ current diversity but also hampering efforts to determine molecular correlates of 
native currents.  
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Figure 1. Action potentials and the surface electrocardiogram. (A) An idealized 
neuronal action potential. INa, sodium current; IK, potassium current; EM, membrane 
potential. (B) An idealized human ventricular myocyte action potential. Phases 0–4 are 
indicated, together with prominent currents during these phases: INa, sodium current; Ito, 
transient outward KV current (generated by KV 4.3); ICa, voltage-gated calcium current 
(generated by CACNA1C, also termed CaV 1.2); IK, potassium current (generated by 
various K+ channels); IKs, slowly activating K
+ current (generated by KCNQ1-
KCNE1); IKr, rapidly activating K
+ current (generated by hERG-KCNE2); IK1, inward 
rectifier K+ current (generated by Kir2.x subfamily α subunits); EM, membrane 
potential. (C) A surface electrocardiogram showing the P and T waves, the QRS 
complex, and the QT interval. 
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Thus, the KCNQ1-KCNE1 channel activates more slowly and at more positive 
membrane potentials than homomeric KCNQ1, and generates the IKs human 
ventricular repolarization current (with possible contributions from other KCNQ1-
KCNE complexes). hERG, the α subunit that generates human ventricular IKr, may be 
regulated by KCNE1, KCNE2 and potentially other KCNEs in vivo; for review, see 
(McCrossan and Abbott, 2004). 
KCNQ1 has a property unique among KV α subunits: it can be converted to a 
constitutively open K+ leak channel (i.e., one that does not require membrane 
depolarization to open) by co-assembly with the KCNE2 or KCNE3 ancillary subunits 
(Schroeder et al., 2000 and Tinel et al., 2000). While it is not yet known whether 
KCNQ1 forms leak channels in human heart with KCNE2 or KCNE3, the ability to 
open constitutively has been shown to facilitate functional roles for KCNQ1-KCNE 
complexes in non-excitable, polarized epithelia in vivo. In gastric parietal cells, 
KCNQ1-KCNE2 channels provide an apical K+ recycling pathway required for gastric 
acidification by the apical gastric H+/K+ATPase (Lee et al., 2000, Heitzmann et al., 
2004 and Roepke et al., 2006). In the colon, basolateral KCNQ1-KCNE3 channels 
help provide a driving force for cAMP-stimulated Cl− secretion (Schroeder et al., 
2000). Recently, we also discovered that KCNQ1 and KCNE2 form a constitutively 
active K+ channel in thyrocytes, and that the KCNQ1-KCNE2 channel is required for 
normal thyroid hormone (TH) biosynthesis (Roepke et al., 2009). Because the heart is 
strongly influenced by the thyroid, the finding suggests that these two K+ channel 
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subunits could influence cardiac function both directly, due to their roles in cardiac 
myocytes, and indirectly, by virtue of their role in thyroid physiology. 
 
 
 
 
Figure 2. KCNE2 and KCNQ1. (A) Topology of KCNQ1 and KCNE2 with respect to 
the cell membrane. (B) Idealized cutaway lateral view of a KCNQ1-KCNE2 complex 
(KCNQ1, grey; KCNE2, red). (C) Cartoon lateral view of a KCNQ1-KCNE2 channel 
complex, stoichiometry as determined for KCNQ1-KCNE1 (Chen et al., 2003a). (D) 
Cartoon top view of a KCNQ1-KCNE2 complex suggesting a possible juxtaposition of 
the two subunit types. 
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2. Pathogenesis 
Mutations in human KCNQ1 and KCNE2 are associated with cardiac arrhythmias, 
thought to be primarily due to disruption of their function in the heart (Wang et al., 
1996 and Abbott et al., 1999). KCNQ1 mutations underlie LQTS Type 1 (LQT1), sub-
classified as Romano Ward Syndrome (RWS; autosomal dominant) and Jervell Lange-
Nielsen Syndrome (JLNS; typically autosomal recessive). Loss-of-function mutations 
in KCNQ1 reduce ventricular repolarization capacity, and therefore extend the QT 
interval on the surface electrocardiogram, hence LQTS. JLNS manifests as both LQTS 
and profound sensorineural deafness – because KCNQ1-KCNE1 channels are 
important not only for ventricular repolarization, but also for K+ secretion into the 
endolymph of the inner ear. Accordingly, loss-of-function KCNE1 mutations, which 
underlie LQT5, also cause either RWS or JLNS; for review, see (Keating and 
Sanguinetti, 2001). Interestingly, gain-of-function mutations in KCNQ1 (and perhaps 
in some KCNE genes) appear to underlie some cases of lone atrial fibrillation (AF), 
probably because they shorten the atrial effective refractory period (Chen et al., 2003b 
and Yang et al., 2004). 
We originally identified KCNE2 as a partner for hERG (KCNH2) and found 
that KCNE2 mutations associate with inherited and drug-induced LQTS, a cardiac 
arrhythmia that predisposes to the often lethal ventricular fibrillation. KCNE2-
associated LQTS is classified LQT6. The presumed mechanism is disruption of 
ventricular myocyte hERG-KCNE2 channels (Abbott et al., 1999). Despite initial 
controversy surrounding these findings, KCNE2 has also since been found by others to 
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regulate IKr in vivo in canine ventricles (Jiang et al., 2004) and mouse sinoatrial node 
(Hesketh et al., 2005). We also found that 3-month-old Kcne2−/− mice (which are 
euthyroid at this age, when bred from Kcne2+/− dams) have impaired ventricular 
myocyte repolarization due to loss of KCNE2 from myocyte channel complexes with 
the KV4.2 and KV1.5 α subunits (Roepke et al., 2008). After these cardiac roles for 
KCNE2 were identified, we discovered that breeding of Kcne2−/− dams results in 
hypothyroidism in both the pregnant dams and their pups, due to a previously 
unreported role for the KCNQ1-KCNE2 K+ channel in thyrocytes (Roepke et al., 
2009). By 3 weeks of age, Kcne2−/− mice born to Kcne2−/− dams show marked cardiac 
abnormalities including cardiomegaly, hypertrophy and impaired contractility. These 
mice also exhibit alopecia, defective skeletal development, 50% embryonic lethality, 
and delayed growth resulting in dwarfism (Roepke et al., 2009); these are all 
symptoms observed in human congenital hypothyroidism (Lafranchi, 2010). While 
Kcne2−/− pups born to Kcne2+/− dams appear to develop normally, and by three 
months are euthyroid (indicating a strong influence of maternal genotype on 
phenotype), they exhibit latent hypothyroidism with cardiomegaly, alopecia, 
diminished T4 and elevated TSH levels by 1 year of age (Roepke et al., 2009) (Fig. 
3A–D). As previously observed in hypothyroid rats (Hapon et al., 2003), Kcne2−/− 
dams have impaired milk ejection – alleviated by oxytocin injection – partially 
explaining the influence of maternal genotype in Kcne2−/− mouse phenotype severity 
(Roepke et al., 2009). 
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Figure 3. Manifestations of thyroid pathology in the Kcne2−/− mouse. Kcne2−/− mice 
have a complex pathophysiology. The primary hypothyroidism due to dysfunction of 
thyrocyte KCNQ1-KCNE2 causes, among other defects: (A) cardiomegaly; (B) 
retarded growth; and alopecia in (C) Kcne2−/− pups from Kcne2−/− dams, and (D) 1-
year-old Kcne2−/− mice originally bred from Kcne2+/− dams. (E) The putative role for 
KCNQ1-KCNE2 (blue) in thyrocytes is to facilitate K+ efflux basolaterally. A subset of 
other channels and transporters are shown for context: Kir7.1, inward rectifier K+ 
channel; NKA, Na+/K+/ATPase; NIS, Na+/I− symporter (yellow). At the apical 
membrane, I− passes from the thyrocyte to the colloid for organification, through 
pendrin or another, unspecified protein (yellow), resulting in formation of thyroglobulin 
(Tg). 
 
The thyroid hormones (THs), thyroxine (T4) and triiodothyronine (T3), are 
crucial for proper growth and development, and play an integral role throughout 
adulthood in maintenance of cognitive function, metabolism, and cardiac function. As 
iodide (I−) is an essential component of TH, the scarcity of dietary I− is a universal 
health concern monitored by the WHO, UNICEF, and the International Council for 
Control of Iodine Deficiency (ICCID) (Zimmermann et al., 2008). I− deficiency 
manifests most severely during pregnancy, when the demand for TH is increased as 
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the early fetus is unable to synthesize TH on its own and must rely on a supply of 
maternal T4 for proper development. Inability to supply the growing fetus with T4 can 
result in fetal mortality, defective neuronal myelination and synapse formation, 
retarded growth and a form of mental retardation known as cretinism (Zimmermann et 
al., 2008). Though severe, defects resulting from hypothyroidism are highly 
preventable with proper intervention. However, controversies surround research aimed 
at determining the population at risk, effective treatment dosage, and the crucial point 
in gestation at which to implement treatment, necessitating further study to elucidate 
the etiology of hypothyroidism, and safe, effective means of its prevention (Loh et al., 
2009). The Na+/I− symporter (NIS) is responsible for the accumulation of I− in 
thyrocytes in the first step of TH biosynthesis. I− is then transported apically into the 
colloid in the thyroid lumen where it is organified into thyroglobin (Tg) and 
subsequently incorporated into T3 and T4. NIS uses the movement of Na+ down its 
concentration gradient to accumulate I− into thyrocytes. While it has previously been 
established that the Na+/K+ATPase, which co-localizes with NIS at the basolateral 
membrane, generates this gradient by pumping Na+ out in exchange for moving K+ in 
(Dohan et al., 2003), the pathway responsible for moving K+ back out of the cell has 
remained enigmatic. Our recent findings show that KCNE2, probably primarily in 
complexes with KCNQ1, is required for normal I− accumulation in the thyroid, 
suggesting that the KCNQ1-KCNE2 channel may form the aforementioned thyrocyte 
K+ efflux pathway (Fig. 3 E). 
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3. Therapy 
Despite there being a long-recognized link between thyroid dysfunction and 
cardiovascular risk, and an awareness that THs regulate expression of K+ channels in 
the heart (Klein and Ojamaa, 2001 and Tribulova et al., 2010), our recent discovery of 
a crucial role for KCNE2 and KCNQ1 in TH biosynthesis presents a novel and 
unexpected genetic link between thyroid dysfunction and cardiac arrhythmias. 
Mutations in KCNE2 and/or KCNQ1 have previously been associated with LQTS, 
AF, and even early-onset myocardial infarction (Wang et al., 1996, Abbott et al., 
1999, Chen et al., 2003b, Yang et al., 2004 and Kathiresan et al., 2009), each of which 
is also predisposed to by thyroid dysfunction in the general population (Forfar et al., 
1979, Hak et al., 2000 and Bakiner et al., 2008), suggesting the intriguing possibility 
of an endocrine component to some KCNE2- and KCNQ1-associated human cardiac 
disease. Whether or not the discovery of KCNQ1-KCNE2 in the thyroid and its role in 
TH biosynthesis leads to use of KCNQ1-KCNE2 modulators to treat thyroid 
dysfunction remains to be seen, but these findings should at least be a consideration in 
future studies of thyroid-related cardiac disease, its molecular etiology and therapy. 
It is noteworthy that subclinical hypothyroidism is associated with 
prolongation of the QTc (QT interval corrected for heart rate) (Tribulova et al., 2010), 
especially given that loss-of-function mutations in KCNQ1 are the joint most 
commonly identified cause of inherited LQTS (Keating and Sanguinetti, 2001), and 
would also be predicted to impair TH biosynthesis by loss-of-function of thyroid 
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KCNQ1-KCNE2 channels, as is achieved by genetic disruption of Kcne2 (Roepke et 
al., 2009). Conversely, ∼10% of AF patients show biochemical evidence of 
hyperthyroidism, and in two-thirds of patients diagnosed with both idiopathic AF and 
hyperthyroidism, successful therapeutic conversion to a euthyroid state is 
accompanied by a return to normal sinus rhythm (Klein and Ojamaa, 2001). One 
genetic cause of AF is gain-of-function of KCNQ1, which shortens the atrial effective 
refractory period, predisposing to AF (Chen et al., 2003b). This raises the interesting 
question of whether increased KCNQ1 function in the thyroid might actually increase 
TH production, something which can initially be tested in mouse models, using 
existing KCNQ1 openers such as the benzodiazepine RL-3. 
In summary, the KCNQ1-KCNE2 K+ channel appears important for normal 
TH biosynthesis in mice, by an as yet incompletely defined mechanism. KCNQ1 and 
KCNE2 are also expressed in human thyroid but we do not yet know their function 
there, or the consequences of their disruption. Disruption of thyrocyte KCNQ1-
KCNE2 in mice is most deleterious to health in pregnant and lactating dams and their 
offspring, and in older mice. A possible role for thyroid dysfunction in KCNQ1- and 
KCNE2-associated cardiac arrhythmias and myocardial infarction warrants 
consideration in future anti-arrhythmic regimes involving pharmacologic modulation 
of KCNQ1. 
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Abstract 
Targeted deletion of the Kcne2 potassium channel β subunit gene ablates gastric acid 
secretion and predisposes to gastric neoplasia in mice. Here, we discovered that Kcne2 
deletion basolaterally reroutes the Kcnq1 α subunit in vivo in parietal cells (PCs), in 
which the normally apical location of the Kcnq1-Kcne2 channel facilitates its essential 
role in gastric acid secretion. Quantitative RT-PCR and Western blotting revealed that 
Kcne2 deletion remodeled fundic Kcne3 (2.9±0.8-fold mRNA increase, n=10; 
5.3±0.4-fold protein increase, n=7) but not Kcne1, 4, or 5, and resulted in basolateral 
Kcnq1-Kcne3 complex formation in Kcne2-/- PCs. Concomitant targeted deletion of 
Kcne3 (creating Kcne2-/- Kcne3-/- mice) restored PC apical Kcnq1 localization without 
Kcne1, 4, or 5 remodeling (assessed by quantitative RT-PCR; n=5-10), indicating 
Kcne3 actively, basolaterally rerouted Kcnq1 in Kcne2-/- PCs. Despite this, Kcne3 
deletion exacerbated gastric hyperplasia in Kcne2-/- mice, and both hypochlorhydria 
and hyperplasia in Kcne2+/- mice, suggesting that Kcne3 up-regulation was beneficial 
in Kcne2-depleted PCs. The findings reveal, in vivo, Kcne-dependent α subunit 
polarized trafficking and the existence and consequences of potassium channel β 
subunit remodeling. 
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Introduction 
Parietal cells (PCs) achieve gastric acidification by virtue of an apical H+/K+ATPase 
(HKA) that pumps protons into the stomach lumen in exchange for K+ ions.  To 
maintain this activity, K+ ions that enter the PC through the HKA must travel back 
into the stomach lumen across the apical membrane.  This K+ ion efflux occurs 
primarily through the heteromeric KCNQ1-KCNE2 K+ channel (1, 2), with other K+ 
channels also possibly contributing (3, 4).  KCNQ1 is a six-transmembrane segment 
(TMS) α subunit from the S4 superfamily that forms functional, voltage-gated, 
homotetrameric K+-selective channels in heterologous expression studies (5, 6).  
KCNE2, originally termed MinK-related peptide 1 (MiRP1), is a 1-TMS ancillary 
subunit from the KCNE gene family (7) (Fig. 1 A).  All five known KCNE gene 
products have been shown to regulate KCNQ1 function in heterologous expression 
studies (8). Two of these - KCNE2 and KCNE3, originally named MiRP2 (7) - endow 
KCNQ1 with constitutive activation, probably by favoring the activated conformation 
of the KCNQ1 voltage sensor (9-11). While KCNE2 and KCNQ1 co-localize in the 
PC apical membrane (Fig. 1 B), KCNQ1-KCNE3 channels target to the basolateral 
membrane of colonic epithelial cells, where they regulate cAMP-stimulated chloride 
secretion (10, 13, 14). 
 Kcnq1–/– mice and Kcne2–/– mice show similar gastric phenotypes, 
characterized by achlorhydria, hypergastrinemia and gastric glandular hyperplasia (1, 
2, 12). PCs from either null show ~10-fold reduced capacity to recover from proton 
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loading, suggesting a primary defect in gastric acid secretion. The achlorhydria we 
previously observed in Kcne2–/– mice was striking given that KCNQ1, the pore-
forming subunit of the complex, was still present, and in fact was strongly expressed 
in double the number of cells per gastric gland in Kcne2–/– mice compared to Kcne2+/+ 
mice (2).  PCs are non-excitable and their membrane potential reportedly varies from -
20 to -40 mV, with stimulation by secretagogues such as gastrin, histamine or 
carbachol causing a shift to the hyperpolarized end of this spectrum (15).  Current-
voltage relationships measured using patch clamp of KCNQ1 alone or with KCNE2 in 
mammalian cell lines indicate that KCNE2 reduces the voltage dependence of KCNQ1 
activation (11); however, in the crucial -20 to -40 mV range, homomeric KCNQ1 
channels appear to actually pass more current (in e.g. 3-second pulses) at neutral pH 
than KCNE2-KCNQ1 complexes.  While KCNQ1 channels are partially inhibited at 
low extracellular pH, KCNE2-KCNQ1 channel currents are increased, but the former 
still pass current even at pH 3, and low pH reduces homomeric KCNQ1 inactivation 
(16).  The polarity of KCNQ1 trafficking would be expected to be fundamental to its 
role in PCs, and disruption of this trafficking an interesting candidate mechanism for 
the profound gastric effects of Kcne2 deletion.  However, previous studies failed to 
find any effects of KCNE subunits on KCNQ1 localization in vitro in Madin-Darby 
Canine Kidney (MDCK) cells (in which KCNQ1 remained basolateral regardless of 
co-expression with each of KCNE1-5) or in vivo in the colonic epithelium (in which 
KCNQ1 was basolateral in both wild-type and Kcne3–/– mice) (14, 17).  Further, we 
recently discovered that KCNQ1-KCNE2 plays a crucial role in thyroid hormone 
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biosynthesis, and that this channel appears to be basolaterally located in thyrocytes 
(18), contrasting with its apical localization in PCs. These apparent paradoxes, and the 
relative lack of understanding of the mechanisms underlying polarized trafficking of 
ion channels in general, prompted us to determine the effects of Kcne gene deletion on 
KCNQ1 trafficking in mouse PCs in vivo.   
 
Materials and Methods 
Generation of gene-targeted mice 
All mice used were housed and utilized according to the NIH Guide for the Care and 
Use of Laboratory Animals and Weill Medical College of Cornell University animal 
care and use policies. Kcne2−/− mice were generated as described previously from 
Kcne2+/− × Kcne2+/− crosses (2). Kcne3 was disrupted through homologous 
recombination, using a targeting vector to replace the entire coding region, contained 
within the fourth exon, of the Kcne3 gene. Two homologous arms, a 3.9-kb sequence 
homologous to the 5′ region upstream from exon 4 and a 3.0-kb sequence homologous 
to the 3′ downstream region, were subcloned into a pVBTk-loxP-knockout backbone 
vector. The vector contained a neomycin resistance (Neor) cassette flanked by LoxP 
sites, allowing for the removal of the cassette on expression of Cre-recombinase, and a 
TK− selection marker (see Fig. 4 A). The targeting vector was linearized at a unique I-
Ceu1 restriction enzyme site outside of the homologous region and electroporated into 
Albino C57BL/6 (C2J) ES cells. Clones were positively selected for Neor, and 
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integration of the null vector was confirmed through Southern blot analysis with a 5′ 
probe directed at a 126-bp sequence located outside the recombined region. The probe 
was amplified by PCR using the following primers: forward 5′-
GCAGAAGGTAGGCACTTGGG-3′ and reverse 5′-
ACTGGGGGAGACAATAGGCG-3′. Correctly targeted ES cells were injected into 
C57BL/6 blastocysts and implanted into female mice, which were bred with C57BL/6 
males to generate chimeric progeny of a 50:50 C57BL/6:Albino B6 (C2J) genetic 
background. Chimeras were interbred to produce Kcne3+/− mice. The Kcne3−/− mice 
used in this study were bred from Kcne3+/− × Kcne3+/− crosses. 
To generate litters of Kcne2+/−Kcne3+/− mice, male Kcne2−/− mice were bred 
with female Kcne3−/− mice. All double-heterozygous mice appeared superficially 
normal and were interbred to yield the Kcne2−/−Kcne3−/− and Kcne2+/−Kcne3−/− mice 
used in experiments. Genotyping for Kcne2 was performed by PCR using the 
following oligonucleotide primers: 5′-CTGGAGGTAGCCAAATGGAGGAAG-3′, 5′-
TCCTGCCAATC TTCCACGATGTAC-3′, and 5′-
CGCTCCCGATTCGCAGCGCATC-3′, which generated a wild-type band of 382 bp 
and a knockout band of 680 bp. Genotyping for Kcne3 was performed by PCR using 
the following oligonucleotide primers: 5′-CTATTCTACACGCACTGTGGGATG-3′, 
5′-CGTTGGAAGTCT CCATAGCAACAG-3′, and 5′-
CGCTCCCGATTCGCAGCGCATC-3′, which generated a wild-type band of 280 bp 
and a knockout band of 1000 bp. 
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Quantitative RT-PCR (qRT-PCR) 
Tissue extraction: Mice were euthanized by CO2 asphyxiation. Stomachs were excised 
and washed in PBS, and the fundus was removed. Tissue was flash-frozen in liquid 
nitrogen and stored at −80°C until use. In preparation for RNA extraction, frozen 
tissue sections were submerged overnight or for 8 h in RNAlater Ice (Ambion, Austin, 
TX, USA) at −20°C. 
 
RNA extraction: RNA was extracted from 30 mg of tissue with RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Tissue 
homogenization was achieved using a pestle grinder system (Fisher Scientific, 
Hampton, NH, USA). RNA yield and purity (A260/A280) were assessed by 
NanoDrop 2000 spectrophotometer (ThermoScientific, Waltham, MA, USA). RNA 
samples with A260/A280 absorbance ratios between 1.80 and 2.10 were considered 
acceptable for cDNA synthesis. 
 
cDNA synthesis: cDNA was synthesized from 1 μg of RNA with Quantitect Reverse 
Transcriptase (Qiagen) according to the manufacturer's protocol. To remove genomic 
DNA, template RNA was mixed with gDNA Wipeout Buffer (Qiagen) and incubated 
at 42°C for 2 min. Quantitect Reverse Transciptase containing an RNase inhibitor and 
Quantiscript RT Buffer containing Mg2+ and dNTPs were then added to the genomic 
DNA elimination reaction and incubated at 42°C for 15 min. The reverse transcription 
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reaction was inactivated with a 3-min incubation at 95°C. Synthesized cDNA was 
analyzed immediately thereafter by qPCR or stored at −20°C until use. 
 
Targeting information: qRT-PCR was conducted adhering as closely as possible to 
MIQE guidelines (19). Primer pairs for target gene Kcne1 [National Center for 
Biotechnology Information (NCBI) GeneID 16509] produced an amplicon of 108 bp; 
match position of the expected sequence was number 1 out of 123 Basic Local 
Alignment Search Tool (BLAST; U.S. National Institutes of Health, Bethesda, MD, 
USA) matches. Primer pairs for target gene Kcne3 (NCBI GeneID 57442) produced an 
amplicon of 143 bp; match position of the expected sequence was number 1 out of 
1001 BLAST matches. Primer pairs for target gene Kcne4 (NCBI GeneID 57814) 
produced an amplicon of 126 bp. Primer pairs for target gene Kcne5 (NCBI GeneID 
66240) produced an amplicon of 113 bp; match position of the expected sequence was 
number 1 out of 428 BLAST matches. Primer pairs for reference gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH; NCBI Gene ID 14433) produced an amplicon 
of 123 bp; match position of the expected sequence is number 1 out of 251 BLAST 
matches. 
 
Primer information: Primer sequences for qPCR analysis were acquired from the 
Harvard Medical School PrimerBank (Boston, MA, USA; ref. 20) and were as 
follows: Kcne1, forward 5′-ATGAGCCTGCCCAATTCCAC-3′ and reverse 5′-
GAGCTGAGACTTACGAGCCA-3′; Kcne2, forward 5′-
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CACATTAGCCAATTTGACCCAGA-3′ and reverse 5′-
GAACATGCCGATCATCACCAT-3′; Kcne3, forward 5′-
CTTTGCTCGATGGAAGGGGAC-3′ and reverse 5′-
GCTGTCGTTGAGAGGCGTC-3′; Kcne4, forward 5′-
CTGAGGATGGAGCCTCTGAAC-3′ and reverse 5′-
AGCAAATCGAAACGAGTCCTTC-3′; Kcne5, forward 5′-
AGATCCGCTGTCCTCCTCATT-3′ and reverse 5′-
GGGTTCTGACCTCTCATCATCTT-3′; and GAPDH, forward 5′-
AGGTCGGTGTGAACGGATTTG-3′ and reverse 5′-
TGTAGACCATGTAGTTGAGGTCA-3′. Primers (50-nm synthesis scale, desalted) 
were acquired from Invitrogen (Carlsbad, CA, USA). 
 
Assay details: qPCR analysis was performed on the Roche Light Cycler 480 System 
using LightCycler 480 SYBR Green I Master Mix and LightCycler 480 96-well white 
plates (Roche Diagnostics, Indianapolis, IN, USA). Each reaction contained ∼75 ng of 
cDNA, 1 μl of PCR-grade water, 2 μl of 10 μM forward primer, 2 μl of 10 μM reverse 
primer, and 10 μl 2X Master Mix, which was comprised of dNTP mix, MgCl2, 
FastStart TaqDNA Polymerase, reaction buffer, and SYBR Green I dye. 
 
Cycling conditions: Thermocycling parameters were as follows: for amplification, 1 
cycle at 95°C (10 min); 45 cycles at 95°C (5 s), 68°C (5 s), and 72°C (25 s); for 
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melting curve, 95°C (1 s), 65°C (1 s), 95°C (continuous); for cooling, 1 cycle 45°C 
(15 s). 
 
Data analysis: Advanced relative quantification was used to obtain normalized 
changes in expression levels of target genes (Kcne1–5) relative to controls (GAPDH) 
using LightCycler 480 1.5 software. Primer pairs were previously validated by 
PrimerBank with amplification plots, dissociation curves, and 2% agarose gel analysis. 
Primer pair amplification efficiency was also established with calibration curves 
within the laboratory on LightCycler 480 equipment, and deemed satisfactory for 
experimentation. The calibration curve for GAPDH yielded a slope of −3.334 and 
efficiency of 1.995. The calibration curve for Kcne1 yielded a slope of −3.386 and 
efficiency of 1.974. The calibration curve for Kcne3 yielded a slope of −3.362 and 
efficiency of 1.983. The calibration curve for Kcne4 yielded a slope of −3.110 and 
efficiency of 2.097. The calibration curve for Kcne5 yielded a slope of −3.315 and 
efficiency of 2.003. Each sample was run in triplicate as a quality control measure, and 
triplicates varying from one another by >1 cycle were discarded. Melting curves were 
assessed for each reaction to verify the amplification of a single product. Final 
analysis of statistical significance was calculated using 1-way analysis of variance 
(ANOVA) test (Origin). 
 
Semiquantitative RT-PCR 
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The observation of Kcne3 up-regulation in Kcne2−/− mouse fundus using qPCR was 
recapitulated using conventional semiquantitative RT-PCR on fundic cDNA, using 
different primer sequences to those used for qPCR, and an alternative reference gene: 
hypoxanthine-guanine phosphoribosyltransferase (HPRT). Briefly, RNA was 
extracted from 4 separate stomach fundi/genotype using an RNAeasy kit (Qiagen), 
then samples were diluted to give equal RNA concentrations, as assessed by 
spectrophotometry, before reverse-transcription to give cDNA as before (21). Primers 
used were as follows: HPRT, forward 5′-TGGAAAGAATGTCTTGATTGTTGA-3′ 
and reverse 5′-ACTTCGAGAGGTCCTTTTCACC-3′, which gives a 130-bp product; 
Kcne3, forward 5′-GGCTCTGAACACAACCCTTC-3′ and reverse 5′-
TTTGTCCACTTTGCGTGAAC-3′, which gives a 205-bp product. Band densities of 
PCR products obtained with specific primers for HPRT transcript, run on a 1% 
agarose gel and stained with ethidium bromide, were measured using a Fluor-S 
MultiImager (Bio-Rad, Hercules, CA, USA) to confirm that the RNA-concentration-
normalized samples each yielded similar amounts of this reference transcript. In 
parallel, cDNA samples from the same preps were amplified with Kcne3-specific 
primers, and optical density was measured. Results are expressed as mean optical 
density for each amplicon, with statistical analysis performed using 1-way ANOVA 
with statistical significance set at P < 0.05. 
 
Immunostaining (IS) and immunofluorescence (IF) 
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KCNQ1 IS (Fig. 1 C–E) was performed as we previously described (2). IF detection 
of HKA β, the Na+K+2Cl− cotransporter (NKCC1), KCNQ1, and KCNE3 was 
performed using a Discovery XT processor (Ventana Medical Systems, Tucson, AZ, 
USA). The primary antibody concentrations used were: 0.5 mg/ml anti-HKA β (mouse 
monoclonal; Affinity Bioreagents, Golden, CO, USA), 0.5 mg/ml anti-NKCC1 (goat 
polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and 1 mg/ml anti-
KCNQ1 (rabbit or goat polyclonal; Chemicon, Temecula, CA, USA); in-house anti-
KCNE3 serum was used at a 1:500 dilution after column-enriching IgG. Preceding the 
primary antibody incubation, the tissue sections were blocked for 30 min in 10% 
normal goat serum, 2% BSA in PBS, followed by 8 min avidin/biotin block. The 
primary antibody incubation (3 h) was followed by 32 min incubation with 
biotinylated anti-mouse IgG (Vectastain ABC kit; Vector Laboratories, Burlingame, 
CA, USA) for HKA β, 60 min incubation with biotinylated anti-goat IgG (Vectastain 
ABC kit) for NKCC1 (and for KCNQ1 for KCNE3 colocalization analysis), and 
biotinylated anti-rabbit or antibody at 1:200 dilution (Vectastain ABC kit) for KCNQ1 
(for HKA and NKCC1 colocalization analysis). The secondary detection was 
performed with Streptavidin-HRP D (Ventana Medical Systems), followed by 
incubation with Tyramide-Alexa Fluor 488 (Invitrogen) or Tyramide Alexa Fluor 568 
(Invitrogen). Stained slides were viewed with a Zeiss Axiovert 200 widefield 
microscope (Carl Zeiss, Oberkochen, Germany), and pictures were acquired using 
MetaMorph 7.1 software (Molecular Devices, Sunnyvale, CA, USA). 
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Western blotting and coimmunoprecipitation (co-IP) 
For Western blotting, gastric membrane fractions were prepared as we previously 
described (2). Protein concentration of the supernatant was measured according to the 
Bradford method. Total protein (40 μg/lane) was loaded into a precast Tris-glycine 4–
20% gel (Bio-Rad) and separated by electrophoresis. Proteins were then transferred 
onto a PVDF membrane (Bio-Rad) and blocked with 5% milk and 0.05% Tween-20 in 
PBS at 4°C on a rocker either for 1–2 h or overnight. Primary antibody incubations (4 
h, room temperature, in 1% milk and 0.05% Tween-20 in PBS) were 1:1000 anti-
KCNQ1 (Chemicon); 1:500 anti-KCNE3 (in-house anti-KCNE3 N terminus or anti-
KCNE3 C terminus from Alomone Labs, Jerusalem, Israel); 1 mg/ml anti-NKCC1 
(Santa Cruz Biotechnology). Membranes were washed 4 times, 20 min each, with 
antibody incubation buffer; incubated with the appropriate secondary antibodies (Bio-
Rad), diluted 1:10,000 in buffer A, for 2 h at room temperature; then washed 4 times, 
20 min each, with buffer A and once for 5 min with PBS. Membranes were incubated 
for 1 min with the SuperSignal ECL reagent (Pierce Biotechnology, Rockford, IL, 
USA), then exposed on BioMax Light Film (Kodak, Rochester, NY, USA) and 
developed using an RP X-OMAT processor (Kodak). For co-IPs, membrane fractions 
in buffer A—150 mM NaCl, 50 mM Tris-HCL (pH 7.4), 20 mM NaF, 10 mM NaVO4, 
1 mM phenylmethylsulfonyl fluoride (Fisher Scientific), 1% Nonidet P-40 (Pierce), 
1% CHAPS (Sigma, St. Louis, MO, USA), 1% Triton X-100 (Fisher Scientific), and 
0.5% SDS (Sigma)—were precleared with Protein A Sepharose beads (Amersham 
Bioscience), incubated with antibodies raised against KCNQ1 or NKCC1, and 
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precipitated with Protein A Sepharose beads; then beads were washed with buffer A, 
and bound proteins were eluted with SDS-PAGE loading buffer for Western blotting 
as above. 
 
Histology 
For histology and stomach mass quantification, mice were killed using CO2 
asphyxiation (5–10/genotype). Stomachs and colons were removed postmortem, 
stomach mass was determined, and stomach and colon tissue was fixed in 10% neutral 
buffered formalin, processed by routine methods, and embedded in paraffin wax. 
Gastric mucosal and colonic epithelial sections were cut at 5-μm intervals, placed on 
positively charged Superfrost slides, stained with hematoxylin and eosin (H&E), and 
evaluated with an Olympus BX45 microscope (New York/New Jersey Scientific Inc., 
Middlebush, NJ, USA). 
 
Whole-stomach pH measurements 
Mice were killed by CO2 asphyxiation. Stomachs were ligated ex vivo at the 
esophageal and duodenal junctures and excised. Stomachs were then incubated for 1 h 
in oxygenated HEPES-buffered Ringer's solution with or without 300 μM histamine 
(Sigma). After 1 h incubation time, stomach contents were aspirated, and pH was 
measured using a microcombination pH probe (Microelectrodes Inc., Bedford, NH, 
USA). 
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Results 
Kcne2 deletion reverses the polarity of Kcnq1 trafficking in PCs 
Having previously determined that Kcnq1 expression in the gastric mucosa is 
increased after targeted deletion of Kcne2 (2), here we examined the effects of Kcne2 
deletion on the intracellular localization of Kcnq1 in PCs. In 3-mo-old Kcne2−/− 
mouse gastric mucosa, Kcnq1 IS demonstrated an apparent sharply basolateral 
localization in PCs across the mucosa, in contrast to its diffuse staining in Kcne2+/+ 
PCs due to localization in the highly convoluted and invaginated apical membrane 
(Fig. 1C–E). Double IF staining confirmed that Kcnq1 was expressed in the apical side 
of PCs from 3-mo-old Kcne2+/+ mice, colocalizing with the H+/K+ATPase β subunit 
(HKA β), a PC apical membrane marker, but not with NKCC1, a marker for 
basolateral membrane in PCs (22) (Fig. 1F, G). In contrast, in age-matched Kcne2−/− 
mouse gastric sections, Kcnq1 was still expressed in PCs (which were identified by 
midgastric gland location and HKA β expression), but was colocalized with NKCC1 
at the PC basolateral membrane (Fig. 1F, G). HKA β was still expressed in the apical 
membrane of PCs, as described previously (23), and did not colocalize with NKCC1 
in either Kcne2+/+ or Kcne2−/− sections, demonstrating that Kcne2 deletion did not 
globally disrupt PC polarity (Fig. 1H). 
 
 127 
 
 
Figure 1. Reversed Kcnq1 trafficking in PCs of Kcne2−/− mice. A) Cartoon of a 
KCNQ1–KCNE2 complex. B) Cartoon of a PC showing HKA, NKCC1, and KCNQ1–
KCNE2. C) KCNQ1 immunostaining (IS) in Kcne2−/− gastric mucosa. Scale bar = 100 
μm. D) Expanded view of black box from panel C. Arrowhead indicates basolateral 
KCNQ1 staining. E) KCNQ1 IS in Kcne2+/+ gastric mucosa (same scale as panel D). 
Arrowhead indicates diffuse KCNQ1 staining due to localization at the invaginated 
apical membrane. F–H) Top: exemplar IF colabeling of Kcne2+/+ and Kcne2−/− gastric 
glands as indicated. Bottom merged panel shows expanded view of the boxed region in 
the top merged panel. Width of view (except bottom merge): 100 μm (F); 75 μm (G, H). 
Blue arrowheads, PC basolateral side; white arrowheads, PC apical side. Representative 
of results from ≥2 mice, 3–5 sections/mouse/genotype. Bottom: cartoons summarizing 
IF data.  
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Kcne2 deletion selectively up-regulates fundic Kcne3 
We considered two possible mechanisms underlying the observed switch in Kcnq1 
location on Kcne2 deletion: passive, arising from homomeric Kcnq1 trafficking to the 
basolateral membrane in the absence of a required chaperone (postulated to be Kcne2) 
to target its expression to the apical side; or active, due to hijacking by another Kcne 
subunit. We therefore next investigated possible Kcne remodeling in Kcne2−/− gastric 
fundus tissue, using qRT-PCR analysis of transcripts for each of the four remaining 
Kcne genes, with GAPDH serving as a reference gene. Strikingly, we observed that 
fundic Kcne3 transcript expression was increased 3-fold at 3 mo of age by targeted 
deletion of Kcne2 (n=10 mice/genotype; P<0.05), whereas there were no significant 
changes in the fundic expression of transcripts for Kcne1, Kcne4, or Kcne5 (n=10 
mice/genotype; P > 0.4) (Fig. 2A). The observation that Kcne3 mRNA was 
upregulated in Kcne2−/− fundus was recapitulated using conventional 
(semiquantitative) RT-PCR, with HPRT as a reference gene (n=4 mice/genotype; 
P<0.01; Fig. 2B, C). Notably, fundic Kcne3 protein expression was found to be 
increased 5-fold by Kcne2 deletion (n=7 independent preps, 21–35 mice/genotype, 
P<1×10−4; Fig. 2D, E). 
Kcne3 forms PC basolateral complexes with Kcnq1 in the absence of Kcne2 
The fundic remodeling data (Fig. 2) suggested Kcne3 as the most likely Kcne 
candidate for diversion of Kcnq1 to the basolateral membrane in Kcne2−/− PCs. We 
adopted several biochemical and genetic approaches to test this hypothesis. First, we 
performed native co-IP studies using fundic tissue, and found greatly increased  
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Figure 2. PC Kcne3 is selectively up-regulated in remodeling arising from targeted 
deletion of Kcne2. A) qRT-PCR analysis of mRNA expression level of Kcne genes 
expressed as a ratio to GAPDH; n=10 mice/genotype/gene. B) Representative 
semiquantitative RT-PCR of gastric mucosal lysates from Kcne2+/+ and Kcne2−/− mice 
for Kcne3 and the reference gene HPRT. C) Mean band optical densities from samples 
as in panel B; n=4 independent preps/genotype. D) Representative Western blot of 
Kcne3 protein in membrane fractions from Kcne2+/+ and Kcne2−/− mouse fundus 
preparations as indicated. Arrows indicate expected sizes of nonglycosylated and fully 
glycosylated (mature) Kcne3. E) Band optical density from Kcne3 (mature form) 
Western blots of Kcne2+/+ and Kcne2−/− gastric mucosal membrane fractions, as in 
panel D; n=7 independent preps from 3–5 stomachs each; total of 21–35 
stomachs/genotype. Error bars = sem. 
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Figure 3: Remodeled Kcne3 forms basolateral complexes with Kcnq1 in Kcne2−/− 
PCs. A) Co-IPs showing complex formation of Kcne3 with Kcnq1 (left) but not with 
NKCC1 (right) from mouse fundic membrane fractions. IPs from Kcne2+/+ and 
Kcne2−/− mice using antibodies against Kcnq1 or NKCC1, and probed with anti-Kcne3 
antibody. Arrow indicates expected mature Kcne3 migration distance. n=2 
experiments/antibody, with each prep pooled from 3–5 mouse stomachs/genotype. B) 
Top: exemplar IF labeling of Kcne3 (red) and Kcnq1 (green) in Kcne2+/+ or Kcne2−/− 
gastric glands, or Kcne2+/+ colonic crypts, as indicated. Bottom merged panel shows 
expanded view of the boxed region. Width of view (except bottom merge): 100 μm. 
Representative of results from at least two mice, 3–5 sections/mouse/genotype. Bottom: 
cartoons summarizing IF data. 
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formation of Kcnq1–Kcne3 complexes in Kcne2−/− tissue compared to Kcne2+/+ 
tissue, with NKCC1 providing a negative control for Kcne3 co-IP (Fig. 3A). These 
data were supported by IF analyses, which indicated increased Kcne3 expression 
compared to Kcne2+/+ PCs, and basolateral colocalization of Kcne3 with Kcnq1, in 
Kcne2−/− PCs— similar to that observed in wild-type colonic epithelium (Fig. 3B). 
Kcne3 is necessary and sufficient for trafficking of Kcnq1 to the PC basolateral 
membrane 
These observations were suggestive of an active role for Kcne3 in rerouting Kcnq1 to 
the PC basolateral membrane, but it was still possible that Kcnq1 could target to the 
PC basolateral side regardless of Kcne3, in the absence of Kcne2. To resolve this, we 
generated Kcne3−/− mice by targeted deletion of the Kcne3 gene (Fig. 4A), and then 
crossed them with Kcne2−/− mice to generate heterozygous, and ultimately double-
knockout, Kcne2−/−Kcne3−/− mice. We confirmed their genotypes with PCR (Fig. 4B) 
and with Western blots from colon tissue, in which Kcne3 is known to be expressed 
(10) (Fig. 4C). Next, we determined whether there was remodeling of Kcne1, Kcne4, 
or Kcne5 due to concomitant Kcne2 and Kcne3 deletion, again using qRT-PCR. These 
experiments did not identify statistically significant changes in mRNA expression of 
these 3 genes; there was a general trend toward reduced expression, but considerable 
variability in expression within each genotype (Fig. 4D). Strikingly, IF studies showed 
that Kcnq1 colocalized in the apical compartment with HKA β, and not basolaterally 
with NKCC1, in Kcne2−/−Kcne3−/− mouse PCs (Fig. 4E, F). As we might have 
expected, Kcnq1 was also apically expressed in Kcne2+/+Kcne3−/− mouse PCs (Fig.  
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Figure 4: Kcne3 deletion restores apical trafficking of Kcnq1 in Kcne2−/− mice. A) 
Targeting strategy for genomic deletion of Kcne3. B) PCR genotyping of wild-type, 
heterozygous, and homozygous single-knockout and double-knockout Kcne2−/− and 
Kcne3−/− mice. C) Western blots of Kcne3 in membrane fractions from colonic crypts 
of Kcne3+/+ and Kcne3−/− mice as indicated, using an in-house antibody raised against 
an N-terminal epitope (left), and a commercial antibody (Alomone) raised against a C-
terminal epitope (right). Arrows indicate band at 37 kDa unique to wild-type tissue. D) 
qRT-PCR analysis of fundic Kcne expression profile expressed as a ratio to that of 
reference gene GAPDH amplified in parallel each time; n=10 mice/single gene deletion 
genotype; n=5 mice/double gene deletion genotype. ND, not determined (for Kcne3, not 
measured in Kcne2−/−Kcne3−/− mice; for Kcne5, unable to detect signal conforming to 
quality controls as described in Materials and Methods). Error bars = sem. E, F) Top: 
exemplar IF colabeling of Kcne2+/+Kcne3−/− and Kcne2−/−Kcne3−/− gastric glands as 
indicated. Bottom two IF panels are merged views of the 3 panels above; bottom merged 
panel shows expanded view of the boxed region in the top merged panel. Blue 
arrowheads, PC basolateral side; white arrowheads, PC apical side. Counterstained with 
DAPI (blue). Representative results from ≥2 mice, 3–5 sections/mouse/genotype. Width 
of view (except bottom merge): 100 μm (E); 50 μm (F). Bottom: cartoons summarizing 
IF data.  
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4E, F). Thus, in PCs, Kcne2 is not required for apical localization of Kcnq1 in the 
absence of Kcne3. However, in the absence of Kcne2, Kcne3 is up-regulated and is 
necessary and sufficient to actively chaperone Kcnq1 to the PC basolateral membrane. 
 
Kcne2 is required for Kcnq1 function at the PC apical membrane 
Our findings suggested that in Kcne2−/−Kcne3+/+ mouse PCs, Kcnq1–Kcne3 channels 
could form an additional basolateral K+ efflux route, but that there would be no apical 
K+ recycling pathway. In contrast, in Kcne2−/−Kcne3−/− mouse PCs, homomeric 
Kcnq1 could potentially provide an apical K+ recycling pathway, but in the absence of 
Kcne2 its functionality might be limited, due to an inability to function efficiently at 
low pH and/or negative membrane potentials. There are several hypothetical 
consequences of these mistrafficking and subunit rearrangement events. Basolateral 
Kcnq1–Kcne3 channels in Kcne2−/−Kcne3+/+ mice could potentially restore some 
gastric acid secretion by alleviating PC K+ accumulation. In contrast, 
Kcne2−/−Kcne3−/− mice would exhibit restored gastric acidification if Kcnq1 was able 
to function alone at the apical membrane, but if homomeric Kcnq1 did not have this 
capability, Kcne2−/−Kcne3−/− mice would potentially have the most severe gastric 
pathology of all the genotypes. Kcne2+/+Kcne3−/− mice would be predicted to have 
normal gastric acidification. 
We tested these hypotheses by measuring stomach mass to quantify gastric 
hyperplasia (one consequence of achlorhydria), and by quantifying gastric luminal pH. 
These studies yielded the striking finding that Kcne3 indeed affected gastric function 
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and cell proliferation in Kcne2-depeleted mice, but not in mice with both Kcne2 
alleles. Thus, 3-mo-old Kcne2−/−Kcne3−/− mice exhibited massive gastric hyperplasia, 
with twofold heavier stomachs than age-matched Kcne2−/−Kcne3+/+ mice, whereas 
Kcne2+/+Kcne3−/− mice had normal stomach mass (Fig. 5A, B). Notably, Kcne3 also 
prevented gastric hyperplasia in Kcne2+/−Kcne3+/+ mice, which had significantly 
smaller stomachs than those of Kcne2+/−Kcne3−/− mice (Fig. 5B). These data were 
supported by results from stomach lumen pH quantification, which indicated that 
Kcne2+/−Kcne3−/− mice had significantly less gastric acidification upon histamine 
stimulation than Kcne2+/−Kcne3+/+ mice, although Kcne3 did not affect the stomach 
lumen pH or response to histamine of Kcne2−/− mice. As expected, Kcne2+/+Kcne3−/− 
mice had normal stomach pH and response to histamine (Fig. 5C). 
These findings are consistent with a novel model in which, in the absence of 
Kcne2, Kcne3 is upregulated and chaperones Kcnq1 to the PC basolateral side. When 
both Kcne3 and Kcne2 are deleted, homomeric Kcnq1 localizes to the apical 
membrane, but without restoration of gastric acidification. This indicates that Kcnq1 
cannot function in the absence of both Kcne2 and Kcne3 in PCs, even if at the apical 
membrane, due either to inhibition by low extracellular pH, inability to constitutively 
activate, or both (Fig. 5D). 
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Implications of Kcne-directed polarized trafficking of Kcnq1 
This study describes two main novel findings: discovery of the capacity of a KCNE 
subunit to act as a polar trafficking chaperone, and identification of KCNE subunit 
remodeling (and its functional consequences) in vivo. In native PCs, Kcnq1 probably 
localizes primarily in deeply invaginated sections of the apical membrane both at rest  
 
 
 
Figure 5: Kcne3 deletion exacerbates gastric hyperplasia and achlorhydria 
in Kcne2-deficient mice. A) Exemplar H&E-stained sections of gastric mucosa 
from 3-mo-old wild-type, Kcne3−/−, Kcne2−/− and double-knockout 
Kcne2−/−Kcne3−/− mice. Scale bar = 250 μm. Representative of ≥2 sections each 
from ≥2 mice/genotype. B) Mean stomach mass measured ex vivo from 3-mo-
old mice, genotypes as indicated, n=6–16. NS, nonsignificant. *P < 0.05; **P < 
2 × 10−4; ***P < 4 × 10−5. C) Mean stomach lumen pH measured ex vivo from 
3-mo-old mice, genotypes as indicated, with (+) or without (−) stimulation with 
300 μM histamine (His); n=3–5. *P < 0.05, **P < 0.03, ***P < 0.002 vs. all 
other His groups; #P < 0.01 vs. all other control groups; ^P < 0.05 vs. 
corresponding control group. D) Summary illustrating Kcne control of Kcnq1 
trafficking in mouse PCs. Error bars = sem. 
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and when stimulated, although a fraction of it may be located in intracellular vesicles 
and move to the apical surface on secretagogue stimulation; in contrast, HKA is 
primarily located in intracellular vesicles until stimulation triggers its trafficking to the 
apical membrane (16, 24). Here, we show that Kcne2 deletion results in Kcnq1 
residing basolaterally in PCs instead, and that Kcne3 is necessary and sufficient for 
this rerouting. In a previous study of MDCK cells, Kcnq1 was basolaterally located 
regardless of which Kcne subunit (subunits 1 through 5) it was heterologously 
coexpressed with (17), and we recently found that Kcnq1–Kcne2 channels are 
basolaterally located in thyrocytes (18). Furthermore, Kcne3 does not appear 
necessary for basolateral location of Kcnq1 in colonic epithelium, although potential 
remodeling of other Kcne subunits was not determined in that study (13). Clearly, the 
influence of Kcne subunits on Kcnq1 targeting in polarized cells is highly cell-type 
specific, perhaps due to differences in expression of proteins such as μ1B, an AP-1 
clathrin adaptor complex that directs polarized trafficking (25,–,27). 
The discovery of Kcne remodeling due to genetic disruption of another Kcne 
subunit has potentially profound implications for the etiology of Kcne-related disease 
states and for study of Kcne-knockout mice. In previous studies examining K+ channel 
α subunit gene deletion, a concern has been that functional redundancy exists given 
the similarity of some α subunits, e.g., Kv3.1 and Kv3.2 (28). Here, studying β 
subunits, we have unearthed a novel remodeling phenomenon, wherein the location of 
the α subunit in the absence of its regular β subunit partner is the polar opposite of that 
observed in wild-type mice—due to hijacking by a remodeled (upregulated), related β 
 137 
 
subunit. We suspect we have merely scratched the surface with respect to the 
prevalence of Kcne subunit remodeling in both model systems and in animal and 
human disease states in a variety of tissues, a hypothesis to be tested further in the 
future. The present findings highlight the importance not only of an apical localization 
per se for Kcnq1, but also the association with Kcne2 for full functionality at the 
apical side. Kcnq1–Kcne3 channels are acid-insensitive (29) and, like Kcnq1–Kcne2, 
are constitutively active, so one would assume they could provide an apical K+ 
recycling conduit if located there, but they could not rescue gastric acid secretion in 
Kcne2−/− mice because they were basolaterally located in parietal cells, although they 
partially restored function in Kcne2+/− mice. By the same token, even when apically 
located, Kcnq1 could not serve as a K+ recycling channel without Kcne2 in PCs—we 
speculate this is because homomeric Kcnq1 is voltage dependent and inhibited by 
acid. Our data suggest that Kcnq1 defaults to the apical side in the absence of Kcne2 
or Kcne3, but further studies are required, perhaps adopting a proteomic approach 
together with the genetic models described here, to determine whether Kcnq1 requires 
an additional subunit to traffic apically in parietal cells, which is either upregulated on 
Kcne2 and Kcne3 double knockout, or simply permitted to associate with Kcnq1 only 
in the absence of these subunits. The mechanism underlying basolateral trafficking of 
Kcnq1– Kcne3 complexes in parietal cells is likely both Kcne3 and parietal cell 
dependent, and its elucidation will require use of chimeric Kcne subunits introduced 
either in vivo or into a suitable polarized parietal cell line; the former is more attractive 
because physiological consequences would be readily assayable. Our co-IP data 
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suggest some (albeit relatively low-level) formation of Kcnq1–Kcne3 complexes even 
in wild-type gastric epithelium, which could correspond to complexes in gastric 
surface cells, or in chief cells, two gastric mucosal cell types suggested to express 
basolateral Kcnq1 and Kcne3; these cells are not located midgastric gland and do not 
express Kcne2 or HKA, and thus are easily distinguishable from PCs in IF studies (13, 
29). Alternatively, Kcnq1–Kcne3 complexes could be occurring even in wild-type 
PCs, again albeit at relatively low levels. Further studies will identify what if any 
function these putative channels perform in PCs, and whether or not these are actually 
mixed Kcnq1–Kcne2–Kcne3 complexes, perhaps with functional characteristics we do 
not yet understand. This type of tripartite complex has been reported for Kcne1, 
Kcne3, and Kcnh3 in mouse brain (30). 
Future work will determine which Kcne subunits or other factors control 
polarized trafficking of Kcnq1 in, e.g., the thyroid, and of other α subunits in polarized 
cells in general, together with a search for the molecular signals that cause, e.g., Kcne3 
transcript up-regulation in Kcne2−/− mouse PCs. The extent to which perturbation of 
this polarized trafficking contributes directly to, or is reflective of compensatory 
remodeling in, the molecular etiology of human diseases of the epithelia and other 
related systems, will be explored—particularly in the light of our recent finding that 
Kcne2−/− mice develop gastritis cystica profunda and gastric neoplasia (31). 
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